RU2436577C2 - Ionic task-1 and task-3 channel inhibitors - Google Patents

Abstract

FIELD: medicine, pharmaceutics. ^ SUBSTANCE: invention refers to pharmacology and medicine, and concerns applications of compounds of formula lb for preparing the drug for treating or preventing respiratory sleeping disorders, central and obstructive sleeping apnoea, obstruction of the upper airways and snore. ^ EFFECT: compounds provide higher clinical effectiveness.

Description

The invention relates to the use of compounds of formulas Ia, Ib, Ic, Id, Ie, If, Ig, Ih and / or Ij

and / or their physiologically compatible salts for the preparation of a medicament for the treatment or prophylaxis of respiratory disorders, respiratory disorders in sleep, attacks of central or obstructive sleep apnea, syndrome of impaired patency of the upper respiratory tract, Chain-Stokes respiration, snoring, impaired central regulation of respiration, sudden infant death, postoperative hypoxia and apnea; muscle respiratory disorders, respiratory disorders after prolonged ventilation, respiratory disorders during adaptation in high mountains, acute and chronic pulmonary disorders with hypoxia and hypercapnia; neurodegenerative disorders, dementia, Alzheimer's disease, Parkinson's disease, Huntington's disease; cancer, breast cancer, lung cancer, colon cancer, and prostate cancer.

The compounds of formulas Ia-Ij and / or their physiologically compatible salts inhibit the so-called TASK potassium channels, in particular the subtypes TASK-1 and / or TASK-3.

Potassium channels are widespread membrane proteins, which, due to their effects on cell membrane potentials, play an important role in many physiological processes. Within the various classes of potassium channels, based on the molecular structure, differences between three large groups that characterize the number of transmembrane domains (2, 4, or 6) are revealed. The group of potassium channels with four transmembrane segments differs from the other two in that each typical representative has two pore domains, as a result of which these channels are also designated as K _2P channels [Coetzee WJ et al .; Molecular diversity of K + channels; Ann. New York Acad. Sci. 1999 (868), 233-285]. According to functional terminology, K _2P channels are characterized by so-called “leakage currents” or “background currents” passing through them, which are of great importance for the resting resting membrane potential and, therefore, the excitability of nerve or muscle cells.

Among the K _2p channels, of particular interest is the TASK family of channels that were not open until the late 1990s, of which five representatives, TASK-1, TASK-2, TASK-3, TASK-4 and TASK-5, were described. Other terms used in the literature for basic genes are KCNK3 or K2P3.1 (= TASK-1), KCNK5 or K2P5.1 (= TASK-2), KCNK9 or K2P9.1 (= TASK-3), KCNK15 or K2P15.1 (= TASK-5) and KCNK17 or K2P17.1 (= TASK-4, TALK-2). The highest homology in this family is noted for channels TASK-1 and TASK-3, in which the amino acid identity is more than 50%. The dimerization of K _2P channels forms functional potassium channels consisting of four pore subunits. Streams passing through these channels are referred to in the literature as IKso stream. In addition to homodimerizing, for example, two TASK-1 or two TASK-3 proteins, heterodimerization of TASK-1 and TASK-3 is also possible in this context [Berg AP, Talley EM, Manger JP, Bayliss DA; Motoneurons express Heteromeric TWIK-related acid-sensitive K ⁺ (TASK) Channels containing TASK-1 (KCNK3) and TASK-3 (KCNK9) subunits; J. Neuroscience 2004 (24), 6693-6702].

In particular, TASK channels are noteworthy due to their extremely strong dependence on extracellular pH fluctuations within the physiological range. At acidic pH, the channels are inhibited, and at alkaline pH, they are activated. Due to this pH dependence, the TASK channels are assigned the physiological function of the sensor, which translates small changes in extracellular pH into the corresponding cellular signals [Duprat F., Lesage F., Fink M., Reyes R., Heurteaux C., Lazdunski M .; TASK, a human background K + channel to sense external pH variations near physiological pH; EMBO J. 1997 (16), 5464-5471; Patel A.J., Honore E .; Properties and modulation of mammalian 2P domain K + channels; Trends Neurosci. 2001 (24), 339-346].

TASK-1 is expressed in the brain and also in the spinal ganglia and some peripheral tissues, such as the pancreas, placenta, uterus, lung, heart, kidney, small intestine, and stomach. Additionally, TASK-1 was found in chemosensitive cells of the brain stem and carotid bodies, as well as in the motor neurons of the hyoid nerve. TASK-3 is mainly expressed in the cerebellum [Medhurst A.D., Rennie G., Chapman C.G., Meadows H., Duckworth M.D., Kelsell R.E., Glober I.I., Pangalos M.N .; Distribution analysis of human two pore domain potassium channels in tissues of the central nervous system and periphery; Mol. Brain Res. 2001 (86), 101-114].

Electric currents induced by the TASK-1 potassium channels were found in the motor neurons of the hyoid nerve (motor cranial nerve, which has the most important function of maintaining the upper respiratory tract) and in the blue spot. It was found that TASK-1 channels are included in the respiratory regulation of respiratory neurons of the brain stem, carotid bodies and motor neurons of the hyoid nerve, as well as in neuroepithelial cells of the lung. In case of impaired breathing (hypoxia, shortness of breath) and in case of physical stress, or due to an increase in the concentration of CO ₂ and the resulting acidosis, or through acid metabolites (lactates), a decrease in pH occurs and, therefore, the pH-dependent TASK-1 channels are blocked. This depolarizes cells, leading to activation of neurons included in respiratory regulation [Buckler KJ, Williams BA, Honore E .; An atom oxygen-, acid- and anaesthetic-sensitive TASK-like background potassium channel in rat arterial chemoreceptor cells; J. Physiol. 2000 (525), 135-142; Bayliss DA, Talley EM, Sirois JE, Lei Q .; TASK-1 is a highly modulated pH-sensitive 'leak' K + channel expressed in brainstem respiratory neurons; Respiration Physiology 2001 (129), 159-174].

An increase in the activity of chemosensitive neurons along with activation of the motor neurons of the hyoid nerve, due to the blockage of the TASK channel, can stimulate respiration and simultaneously stabilize the upper respiratory tract and protect them from collapse and occlusion. Moreover, through the mechanism of stabilization of the upper respiratory tract, snoring can be suppressed. Therefore, blocking TASK-1 ion channels can be used in the treatment of respiratory disorders, for example, sleep apnea.

Attacks of obstructive sleep apnea occur when there is compression of the upper respiratory tract, due to reduced inspiratory pressure, which is created by the muscles of the diaphragm and chest during contraction of the upper respiratory tract during inhalation into the upper respiratory tract. Anatomical constriction of the upper respiratory tract occurs with obesity (lipotrophy) and anatomical predisposition (e.g. retrognathia). In people with such a predisposition, the tone of the stretching muscle structure related to the muscle structure of the upper respiratory tract should always be increased compared with healthy people in order to prevent collapse. The chin-lingual muscle (the muscle at the base of the tongue) is the most important muscle of the stretching muscles of the upper respiratory tract; it is innervated by the hyoid nerve. While in the waking state, the muscle tone of the upper respiratory tract is still high enough to prevent respiratory distress, in sleep state it decreases significantly, so that when the inspiratory pressure is reduced, it is too low. This imbalance leads to a collapse of the upper respiratory tract (obstructive apnea) during inhalation. In the case of significant constriction of the upper respiratory tract and, accordingly, high tissue tension, respiratory arrest can occur even on exhalation, that is, without lowering the pressure. Therefore, an increase in muscle tone of the upper respiratory tract through the use of Kv1.5 inhibitors having the features of the invention prevents attacks of obstructive apnea.

Snoring is caused by fluctuations in the flow of air in the upper respiratory tract. It occurs with excessively narrow upper respiratory tracts simultaneously with insufficient muscle tone of the upper respiratory tract and, therefore, is pathophysiologically close to attacks of nocturnal obstructive apnea. Thus, snoring can be seen to some extent as a precursor to obstructive apnea. Therefore, an increase in muscle tone of the upper respiratory tract with the help of Kv1.5 inhibitors, which have the features of the invention, prevents snoring and attacks of obstructive sleep apnea.

Attacks of central apnea are caused by central respiratory dysregulation. They are prevented by the combined exposure of the inventive Kv1.5 inhibitors stimulating respiration (effect on minute volume of respiration).

TASK-1 canals are also located in the smooth muscle cells of the mesenteric and pulmonary arteries. Possibly, in the latter they are included in pulmonary vasoconstriction induced by acidosis [Gurney A.M., Osipenko O.N., MacMillan D., McFarlane K.M., Tate R.J., Kempsill F.E .; Two-pore domain K channel, TASK-1, in pulmonary artery smooth muscle cells; Circ. Res. 2003 (93), 957-964].

It was also found that TASK channels are included in the secretion of adrenal hormones in the glomerular zone of the adrenal cortex [Czirjak G., Fischer T., Spät A., Lesage F., Enyedi P .; TASK (TWIK-related acid-sensitive K + channel) is expressed in glomerulosa cells of rat adrenal cortex and inhibited by angiotensin II; Molecular Endocrinology 2000 (14), 863-874].

On cultured granular cells of the cerebellum, it was shown that genetic inactivation of TASK channels leads to neuroprotective effects [Lauritzen I., Zanzouri M., Honoré E., Duprat F., Ehrengruber M.U., Lazdunski M., Patel A.J .; K + -dependent cerebellar granule neuron apoptosis - Role of Task leak K + channels; J. Biol. Chem. 2003 (278), 32068-32076]. In addition, it has been shown that TASK-1 channels are responsible for programmed death (apoptosis) of granular cells, and that cell death can be prevented by blocking TASK-3. Therefore, it is believed that the development of special inhibitors of TASK-1/3 channels may mean a pharmacological strategy for the treatment of neurodegenerative disorders [Patel A.J., Lazdunski M., The 2P-domain K + channels: role in apoptosis and tumorigenesis, Pflugers Arch. 2004 (448), 261-273].

The TASK-3 gene is amplified and overexpressed in various tissues of human carcinoma, such as breast cancer, lung cancer, colon cancer, and metastatic prostate cancer [Mu D., Chen L, Zhang X., et al., Genomic amplification and oncogenic properties of the KCNK9 potassium channel gene, Cancer Cell 2003 (3), 297-302]. It was found that the implementation of a point mutation on TASK-3 disables the function of the channel and at the same time eliminates the tumor-forming function. Therefore, it is believed that TASK-3 antagonists could reduce the growth of various types of human cancer, thus creating a new family of anti-cancer drugs [Pei L., Wiser O., Slavin A., Mu D., Powers S., Jan LY, Hoey T .; Oncogenic potential of TASK 3 (Kcnk9) depends on K + channel function; Proc. Natl. Acad. Sci. USA 2003 (100), 7803-7807].

Despite the great physiological significance of TASK channels, to date, only a very small number of pharmacological modulators of these channels are known in the literature. It was found that activation of the TASK-1 channel can be achieved using therapeutic concentrations of inhaled anesthetics, halothane and isoflurane [Patel AJ, Honoré E., Lesage F., Fink M., Romey G., Lazdunski M .; inhalational anesthetics activate two-pore-domain background K + channels; Nature Neurosci. 1999 (2), 422-426]. The only known direct blockers of TASK-1 are arachidonamides, anandamide (an endogenous cannabinoid receptor ligand) and its methanandamide homolog, for which an IC ₅₀ value of 0.7 μm was established [Maingret F., Patel AJ, Lazdunski M., Honoré E. ; The endocannabinoid anandamide is a direct and selective blocker of the background K + channel TASK-1; EMBO J. 2001 (20), 47-54]; as well as doxapram, which is used to treat respiratory disorders, and for which an IC ₅₀ value of 0.4 μm has recently been described [Cotten JF, Keshavaprasad B., Laster MJ, Eger EI, Yost CS; The Ventilatory Stimulant Doxapram Inhibits TASK Tandem Pore (K _2p ) Potassium Channel Function but Does Not Affect Minimum Alveolar Anesthetic Concentration; Anesth. Analg. 2006 (102) 779-785].

It has now been found that compounds of formulas Ia, Ib, Ic, Id, Ie, If, Ig, Ih and Ij are potent blockers of TASK channels, in particular, subtypes TASK-1 and TASK-3. Until now, the compounds were known only as Kv1.5 channel blockers, which belong to the group of potassium channels with 6 transmembrane domains and one pore domain (WO 01/00573, WO 01/025189, WO 02/044137, WO 02/046162, WO 02/048131, WO 02/087568, WO 02/088073, WO 02/100825). Due to the significant structural differences between the Kv1.5 channels and the TASK channels, the effects of these compounds, known as Kv1.5 blockers, on the TASK-1 and TASK-3 channels seemed surprising.

Due to their ability to inhibit TASK-1 and / or TASK-3, the compounds of formulas Ia-Ij and / or their pharmaceutically compatible salts are suitable for the prevention and treatment of disorders caused by activation of TASK-1 and / or TASK-3, or the presence of activated TASK- 1 and / or TASK-3, as well as those disorders in which a disorder associated with TASK-1 and / or TASK-3 is a secondary cause.

The compounds of formulas Ia, Ib, Ic, Id, Ie, If, Ig, Ih and Ij and / or their physiologically compatible salts can also be used to treat and prevent disorders when TASK-1 and / or TASK-3 inhibit only partially, for example, using a lower dosage.

In particular, the compounds of formulas (la-1j) can be used for the treatment or prevention of respiratory disorders, respiratory disorders in sleep, attacks of central and obstructive sleep apnea, Cheyne-Stokes breathing, snoring, central breathing disorders, sudden infant death, postoperative hypoxia and apnea; muscle respiratory disorders, respiratory disorders after prolonged ventilation, respiratory disorders during adaptation in high mountains, acute and chronic pulmonary disorders with hypoxia and hypercapnia, neurodegenerative disorders, dementia, Alzheimer's disease, Parkinson's disease, Huntington's disease, cancer, breast cancer , lung cancer, colon cancer, and prostate cancer.

When using the inventive compounds of formulas Ia-Ij, in addition to the described blocking of TASK channels, inhibition of other potassium channels, for example, Kv channels, may also be appropriate in the treatment or prevention of respiratory disorders, respiratory sleep disorders, central and obstructive apnea attacks in a dream; upper respiratory tract obstruction syndrome, Cheyne-Stokes respiration, snoring, central respiratory dysregulation, sudden infant death, postoperative hypoxia and apnea; muscle respiratory disorders, respiratory disorders after prolonged ventilation, respiratory disorders during adaptation in high mountains, acute and chronic pulmonary disorders with hypoxia and hypercapnia.

The present invention relates to the use of Kv1.5 inhibitors for the manufacture of a medicament for the treatment or prophylaxis of respiratory disorders, sleep respiratory disorders, central and obstructive sleep apnea attacks, upper respiratory tract obstruction syndrome, Chain-Stokes respiration, snoring, central regulation disorders breathing, sudden infant death, postoperative hypoxia and apnea; muscle respiratory disorders, respiratory disorders after prolonged ventilation, respiratory disorders during adaptation in high mountains, acute and chronic pulmonary disorders with hypoxia and hypercapnia; neurodegenerative disorders, dementia, Alzheimer's disease, Parkinson's disease, Huntington's disease; cancer, breast cancer, lung cancer, colon cancer, and prostate cancer.

The invention relates to the use of compounds of formulas Ia

where R (8) is either a 1-indanyl radical of formula II or a 2-indanyl radical of formula III

in which

R (1) and R (2),

each independently, is R (20) —C _r H _2r ,

where one CH ₂ group C _r H _2r groups may be substituted by —O—, —CH = CH—, —C = C—, —CO—, —CO — O—, —O — CO—, —S—, - SO-, -SO ₂ -, -NR (21) - or -CONR (21);

R (21) is a hydrogen atom or an alkyl having 1, 2 or 3 carbon atoms;

R (20) is H, CH ₃ , CH ₂ F, CHF ₂ , CF ₃ , C ₂ F ₅ , C ₃ F ₇ , cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms, NR (22 ) R (23), -CONR (22) R (23), -OR (24), -COOR (24), phenyl or an N-containing heterocycle having 1, 2, 3, 4, 5, 6, 7, 8 or 9 carbon atoms,

where phenyl and the N-containing heterocycle are unsubstituted or substituted by one or two substituents selected from the group consisting of F, Cl, Br, I, CF ₃ , NO ₂ , CN, NH ₂ , OH, methyl, ethyl, hydroxymethyl, hydroxyethyl , methoxy, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino;

R (22) and R (23),

each independently represent a hydrogen atom or alkyl having 1, 2, 3 or 4 carbon atoms;

or

R (22) and R (23)

together represent a chain consisting of 4 or 5 methylene groups, of which one CH ₂ group may be substituted with —O—, —S—, —NH—, —N (methyl) - or —N (benzyl) -;

R (24) is a hydrogen atom or an alkyl having 1, 2 or 3 carbon atoms;

r is zero, 1, 2, 3, 4, 5, 6, 7, or 8;

or

R (1) and R (2)

together represent a chain consisting of 4 or 5 methylene groups, of which one CH ₂ group may be substituted with —O—, —S—, —NH—, —N (methyl) - or —N (benzyl) -;

R (3), R (4), R (5) and R (6),

each independently, is a hydrogen atom, F, Cl, Br, I, alkyl having 1, 2, 3, 4 or 5 carbon atoms, cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms, CN, CF ₃ , NO ₂ , OR (25) or NR (26) R (27);

R (25) is a hydrogen atom, an alkyl having 1, 2, 3 or 4 carbon atoms, a fluorinated alkyl radical of the formula —C _x H _2x CF _y H _3-y, or phenyl,

which is unsubstituted or substituted by one or two substituents selected from the group consisting of F, Cl, Br, I, CF ₃ , NO ₂ , CN, NH ₂ , OH, methyl, ethyl, methoxy, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino ;

x is 0, 1, 2, or 3;

y takes values 1, 2 or 3;

R (26) and R (27),

each independently, is a hydrogen atom or an alkyl having 1, 2, 3 or 4 carbon atoms;

or

R (26) and R (27)

together they represent a chain of 4 or 5 methylene groups, of which one CH ₂ group may be substituted with —O—, —S—, —NH—, —N (methyl) - or —N (benzyl) -;

R (7) is a hydrogen atom or an alkyl having 1, 2, 3 or 4 carbon atoms;

R (9) represents a hydrogen atom, OR (28) or OCOR (28);

R (28) is a hydrogen atom or an alkyl having 1, 2, 3 or 4 carbon atoms;

R (10) and R (11),

each independently, is a hydrogen atom or an alkyl having 1, 2, 3 or 4 carbon atoms;

R (12), R (13), R (14) and R (15),

each independently, is a hydrogen atom, F, Cl, Br, I, alkyl having 1, 2, 3, 4 or 5 carbon atoms, cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms, —CN, —CF ₃ , —C ₂ F ₅ , —C ₃ F ₇ , —N ₃ , —NO ₂ , —YC _s H _2s —R (29), phenyl, thienyl, furyl, or an N-containing heterocycle having 1, 2 , 3, 4, 5, 6, 7, 8 or 9 carbon atoms,

where phenyl, thienyl, furyl and an N-containing heterocycle are unsubstituted or substituted by one or two substituents selected from the group consisting of F, Cl, Br, I, CF ₃ , NO ₂ , CN, NH ₂ , OH, methyl, ethyl, methoxy, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino;

Y represents -O-, -CO-, -CO-O-, -O-CO-, -S-, -SO-, -SO ₂ -, -O-SO ₂ -, -SO ₂ NR (30) -, -CONR (30) - or -NR (30) CO-, where the bond with the main structure in each case is through an atom located on the left;

R (30) is a hydrogen atom or an alkyl having 1, 2 or 3 carbon atoms;

s is zero, 1, 2, 3, 4, 5, or 6;

R (29) is a hydrogen atom, methyl, CF ₃ , C ₂ H ₅ , C ₃ F ₇ , cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms, -OR (31), -COOR (31 ), —NR (32) R (33), —CONR (32) R (33), phenyl or an N-containing heterocycle having 1, 2, 3, 4, 5, 6, 7, 8, or 9 carbon atoms,

where phenyl and the N-containing heterocycle are unsubstituted or substituted by one or two substituents selected from the group consisting of F, Cl, Br, I, CF ₃ , NO ₂ , CN, NH ₂ , OH, methyl, ethyl, methoxy, dimethylamino , sulfamoyl, methylsulfonyl and methylsulfonylamino;

R (31) is a hydrogen atom or an alkyl having 1, 2 or 3 carbon atoms;

R (32) and R (33)

are each independently a hydrogen atom or an alkyl having 1, 2, 3 or 4 carbon atoms;

or

R (32) and R (33)

together they are a chain of 4 or 5 methylene groups, of which one CH ₂ group may be substituted with —O—, —S—, —NH—, —N (CH ₃ ) - or —N (benzyl) -;

and / or compounds of formula Ib

wherein

R (1) are C (O) OR (9), SO ₂ R (10), COR (11), C (O) NR (12) R (13) or C (S) NR (12) R ( 13);

R (9) is C _x H _2x -R (14);

x takes values 0, 1, 2, 3 or 4,

where x cannot be zero when R (14) is OR (15) or SO ₂ Me;

R (14) is alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, cycloalkyl having 3, 4, 5, 6, 7, 8, 9, 10 or 11 carbon atoms, CF ₃ , C ₂ F ₅ , C ₃ F ₇ , CH ₂ F, CHF ₂ , OR (15), SO ₂ Me, phenyl, naphthyl, biphenyl, furyl, thienyl or an N-containing aromatic heterocycle having 1, 2, 3, 4, 5 6, 7, 8 or 9 carbon atoms,

where phenyl, naphthyl, biphenylyl, furyl, thienyl and the N-containing aromatic heterocycle are unsubstituted or substituted by 1, 2 or 3 substituents selected from the group consisting of F, Cl, Br, I, CF ₃ , OCF ₃ , NO ₂ , CN, COOMe, CONH ₂ , COMe, NH ₂ , OH, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 and 4 carbon atoms, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino;

R (15) is alkyl having 1, 2, 3, 4 or 5 carbon atoms, cycloalkyl having 3, 4, 5 or 6 carbon atoms, CF ₃ or phenyl,

which is unsubstituted or substituted by 1, 2 or 3 substituents selected from the group consisting of F, Cl, Br, I, CF ₃ , NO ₂ , CN, COOMe, CONH ₂ , COMe, NH ₂ , OH, alkyl having 1 , 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino;

R (10), R (11) and R (12),

each independently determined analogously to R (9);

R (13) is a hydrogen atom, an alkyl having 1, 2, 3 or 4 carbon atoms or CF ₃ ;

R (2) is a hydrogen atom, an alkyl having 1, 2, 3 or 4 carbon atoms, or CF ₃ ;

R (3) is C _y H _2y —R (16);

y takes values 0, 1, 2, 3 or 4,

where y cannot be zero when R (16) is OR (17) or SO ₂ Me;

R (16) is alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, cycloalkyl having 3, 4, 5, 6, 7, 8, 9, 10 or 11 carbon atoms, CF ₃ , C ₂ F ₅ , C ₃ F ₇ , CH ₂ F, CHF ₂ , OR (17), SO ₂ Me, phenyl, naphthyl, furyl, thienyl or an N-containing aromatic heterocycle having 1, 2, 3, 4, 5, 6 , 7, 8 or 9 carbon atoms,

where phenyl, naphthyl, furyl, thienyl and an N-containing aromatic heterocycle are unsubstituted or substituted by 1, 2 or 3 substituents selected from the group consisting of F, Cl, Br, I, CF ₃ , OCF ₃ , NO ₂ , CN, COOMe, CONH ₂ , COMe, NH ₂ , OH, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino;

R (17) is a hydrogen atom, alkyl having 1, 2, 3, 4 or 5 carbon atoms, cycloalkyl having 3, 4, 5 or 6 carbon atoms, CF ₃ , phenyl or 2-, 3- or 4-pyridyl ,

where phenyl or 2-, 3- or 4-pyridyl are unsubstituted or substituted by 1, 2 or 3 substituents selected from the group consisting of F, Cl, Br, I, CF ₃ , OCF ₃ , NO ₂ , CN, COOMe, CONH ₂ , COMe, NH ₂ , OH, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino;

or

R (3) is CHR (18) R (19);

R (18) is a hydrogen atom or C _z H _2z —R (16), where R (16) is as defined above;

z is 0, 1, 2 or 3;

R (19) is COOH, CONH ₂ , CONR (20) R (21), COOR (22), CH ₂ OH;

R (20) is a hydrogen atom, an alkyl having 1, 2, 3, 4 or 5 carbon atoms, C _v H _2v —CF ₃ or C _w H _{2w —} phenyl,

where the phenyl ring is unsubstituted or substituted by 1, 2 or 3 substituents selected from the group consisting of F, Cl, Br, I, CF ₃ , OCF ₃ , NO ₂ , CN, COOMe, CONH ₂ , COMe, NH ₂ , OH alkyl, having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino;

v takes values 0, 1, 2 or 3;

w takes the values 0, 1, 2 or 3;

R (21) is a hydrogen atom or an alkyl having 1, 2, 3, 4 or 5 carbon atoms;

R (22) is an alkyl having 1, 2, 3, 4 or 5 carbon atoms;

R (4) is a hydrogen atom, an alkyl having 1, 2, 3, 4, 5, or 6 carbon atoms or CF ₃ ;

or

R (3) and R (4)

together they are a chain of 4 or 5 methylene groups, of which one methylene group may be substituted by —O—, —S—, —NH—, —N (methyl) - or —N (benzyl) -;

R (5), R (6), R (7) and R (8),

each independently represent a hydrogen atom, F, Cl, Br, I, CF ₃ , NO ₂ , CN, COOMe, CONH ₂ , COMe, NH ₂ , OH, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, methylsulfonyl or methylsulfonylamino;

R (30) and R (31),

each independently is a hydrogen atom or an alkyl having 1, 2 or 3 carbon atoms;

or

R (30) and R (31)

together represent a chain of 2 methylene groups;

and / or compounds of formula Ic

wherein

A1, A2, A3, A4, A5, A6, A7 and A8,

each independently represents a nitrogen atom, CH or CR5, where at least four of these groups are CH;

R (1) is C (O) OR (9), SO ₂ R (10), COR (11), C (O) NR (12) R (13) or C (S) NR (12) R (13 );

R (9), R (10), R (11) and R (12),

each independently, represent C _x H _2x -R (14);

x is 0, 1, 2, 3 or 4;

where x cannot be 0 when R (14) is OR (15) or SO ₂ Me;

R (14) is alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, cycloalkyl having 3, 4, 5, 6, 7, 8, 9, 10 or 11 carbon atoms, CF ₃ , C ₂ F ₅ , C ₃ F ₇ , CH ₂ F, CHF ₂ , OR (15), SO ₂ Me, phenyl, naphthyl, biphenylyl, furyl, thienyl or an N-containing aromatic heterocycle having 1, 2, 3, 4, 5, 6, 7, 8 or 9 carbon atoms,

where phenyl, naphthyl, biphenylyl, furyl, thienyl and an N-containing aromatic heterocycle are unsubstituted or substituted by 1, 2 or 3 substituents selected from the group consisting of F, Cl, Br, I, CF ₃ , OCF ₃ , NO ₂ , CN, COOMe, CONH ₂ , COMe, NH ₂ , OH, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino;

R (15) is alkyl having 1, 2, 3, 4 or 5 carbon atoms, cycloalkyl having 3, 4, 5 or 6 carbon atoms, CF ₃ or phenyl, which is unsubstituted or substituted with 1, 2 or 3 substituents, selected from the group consisting of F, Cl, Br, I, CF ₃ , NO ₂ , CN, COOMe, CONH ₂ , COMe, NH ₂ , OH, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1 , 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino;

R (13) is a hydrogen atom, an alkyl having 1, 2, 3 or 4 carbon atoms or CF ₃ ;

R (2) is a hydrogen atom, an alkyl having 1, 2, 3 or 4 carbon atoms or CF ₃ ;

R (3) are C _y H _2y —R (16);

y takes values 0, 1, 2, 3 or 4,

where y cannot be 0 when R (16) is OR (17) or SO ₂ Me;

R (16) is alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, cycloalkyl having 3, 4, 5, 6, 7, 8, 9, 10 or 11 carbon atoms, CF ₃ , C ₂ F ₅ , C ₃ F ₇ , CH ₂ F, CHF ₂ , OR (17), SO ₂ Me, phenyl, naphthyl, furyl, thienyl or an N-containing aromatic heterocycle having 1, 2, 3, 4, 5, 6 , 7, 8 or 9 carbon atoms,

where phenyl, naphthyl, furyl, thienyl and an N-containing aromatic heterocycle are unsubstituted or substituted by 1, 2 or 3 substituents selected from the group consisting of F, Cl, Br, I, CF ₃ , OCF ₃ , NO ₂ , CN, COOMe, CONH ₂ , COMe, NH ₂ , OH, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino,

R (17) is a hydrogen atom, alkyl having 1, 2, 3, 4 or 5 carbon atoms, cycloalkyl having 3, 4, 5 or 6 carbon atoms, CF ₃ , phenyl or 2-, 3- or 4-pyridyl ,

where phenyl or 2-, 3- or 4-pyridyl are unsubstituted or substituted by 1, 2 or 3 substituents selected from the group consisting of F, Cl, Br, I, CF ₃ , OCF ₃ , NO ₂ , CN, COOMe, CONH ₂ , COMe, NH ₂ , OH, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino;

or

R (3) is CHR (18) R (19);

R (18) is a hydrogen atom or C _z H _2z —R (16), where R (16) is as defined above;

z is 0, 1, 2 or 3;

R (19) is COOH, CONH ₂ , CONR (20) R (21), COOR (22) or CH ₂ OH;

R (20) is a hydrogen atom, an alkyl having 1, 2, 3, 4 or 5 carbon atoms, C _v H _2v —CF ₃ or C _w H _{2w —} phenyl,

where the phenyl ring is unsubstituted or substituted by 1, 2 or 3 substituents selected from the group consisting of F, Cl, Br, I, CF ₃ , NO ₂ , CN, COOMe, CONH ₂ , COMe, NH ₂ , OH, alkyl, having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino;

v takes values 0, 1, 2 or 3;

w takes values 0, 1, 2 or 3;

R (21) is a hydrogen atom or an alkyl having 1, 2, 3, 4 or 5 carbon atoms;

R (22) is an alkyl having 1, 2, 3, 4 or 5 carbon atoms;

R (4) is a hydrogen atom, an alkyl having 1, 2, 3, 4, 5, or 6 carbon atoms or CF ₃ ;

or

R (3) and R (4)

together they are a chain of 4 or 5 methylene groups, of which one methylene group may be substituted by —O—, —S—, —NH—, —N (methyl) - or —N (benzyl) -;

R (5) is F, Cl, Br, I, CF ₃ , NO ₂ , CN, COOMe, CONH ₂ , COMe, NH ₂ , OH, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1 , 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, methylsulfonyl or methylsulfonylamino, where in the case where a series of A1-A8 radicals are defined as CR (5), the radicals R (5) are each independently determined;

R (30) and R (31),

each independently, is a hydrogen atom or an alkyl having 1, 2 or 3 carbon atoms;

or

R (30) and R (31)

together represent a chain of 2 methylene groups;

and / or compounds of formula Id

in which

A1, A2, A3, A4, A5, A6, A7 and A8 each independently represent a nitrogen atom, CH or CR (5), where at least one of these groups represents a nitrogen atom and at least 4 of these groups represents CH;

R (1) are C (O) OR (9), SO ₂ R (10), COR (11), C (O) NR (12) R (13) or C (S) NR (12) R ( 13);

R (9), R (10), R (11) and R (12),

each independently represents C _x H _2x -R (14);

x is 0, 1, 2, 3 or 4;

where x cannot be 0 when R (14) is OR (15) or SO ₂ Me;

R (14) is alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, cycloalkyl having 3, 4, 5, 6, 7, 8, 9, 10 or 11 carbon atoms, CF ₃ , C ₂ F ₅ , C ₃ F ₇ , CH ₂ F, CHF ₂ , OR (15), SO ₂ Me, phenyl, naphthyl, biphenylyl, furyl, thienyl or an N-containing aromatic heterocycle having 1, 2, 3, 4, 5 6, 7, 8 or 9 carbon atoms,

where phenyl, naphthyl, biphenylyl, furyl, thienyl and an N-containing aromatic heterocycle are unsubstituted or substituted by 1, 2 or 3 substituents selected from the group consisting of F, Cl, Br, I, CF ₃ , OCF ₃ , NO ₂ , CN, COOMe, CONH ₂ , COMe, NH ₂ , OH, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino;

R (15) is alkyl having 1, 2, 3, 4 or 5 carbon atoms, cycloalkyl having 3, 4, 5 or 6 carbon atoms, CF ₃ or phenyl, which is unsubstituted or substituted with 1, 2 or 3 substituents, selected from the group consisting of F, Cl, Br, I, CF ₃ , NO ₂ , CN, COOMe, CONH ₂ , COMe, NH ₂ , OH, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atom, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino;

R (13) is a hydrogen atom, an alkyl having 1, 2, 3 or 4 carbon atoms or CF ₃ ;

R (2) is a hydrogen atom, an alkyl having 1, 2, 3 or 4 carbon atoms or CF ₃ ;

R (3) are C _y H _2y —R (16);

y takes values 0, 1, 2, 3 or 4,

where y cannot be 0 when R (16) is OR (17) or SO ₂ Me;

R (16) is alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, cycloalkyl having 3, 4, 5, 6, 7, 8, 9, 10 or 11 carbon atoms, CF ₃ , C ₂ F ₅ , C ₃ F ₇ , CH ₂ F, CHF ₂ , OR (17), SO ₂ Me, phenyl, naphthyl, furyl, thienyl or an N-containing aromatic heterocycle having 1, 2, 3, 4, 5, 6 , 7, 8 or 9 carbon atoms,

where phenyl, naphthyl, furyl, thienyl and an N-containing aromatic heterocycle are unsubstituted or substituted by 1, 2 or 3 substituents selected from the group consisting of F, Cl, Br, I, CF ₃ , OCF ₃ , NO ₂ , CN, COOMe, CONH ₂ , COMe, NH ₂ , OH, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino,

R (17) is a hydrogen atom, alkyl having 1, 2, 3, 4 or 5 carbon atoms, cycloalkyl having 3, 4, 5 or 6 carbon atoms, CF ₃ , phenyl or 2-, 3- or 4-pyridyl ,

where phenyl or 2-, 3- or 4-pyridyl are unsubstituted or substituted with 1, 2 or 3 substituents selected from the group consisting of F, Cl, Br, I, CF ₃ , OCF ₃ , NO ₂ , CN, COOMe, CONH ₂ , COMe, NH ₂ , OH, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino;

or

R (3) is CHR (18) R (19);

R (18) is a hydrogen atom or C _z H _2z —R (16), where R (16) is as defined above;

z is 0, 1, 2 or 3;

R (19) is COOH, CONH ₂ , CONR (20) R (21), COOR (22) or CH ₂ OH;

R (20) is a hydrogen atom, an alkyl having 1, 2, 3, 4 or 5 carbon atoms, C _v H _2v —CF ₃ or C _w H _{2w —} phenyl,

where the phenyl ring is unsubstituted or substituted by 1, 2 or 3 substituents selected from the group consisting of F, Cl, Br, I, CF ₃ , OCF ₃ , NO ₂ , CN, COOMe, CONH ₂ , COMe, NH ₂ , OH alkyl, having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino;

v takes values 0, 1, 2 or 3;

w takes values 0, 1, 2 or 3;

R (21) is a hydrogen atom or an alkyl having 1, 2, 3, 4 or 5 carbon atoms;

R (22) is an alkyl having 1, 2, 3, 4 or 5 carbon atoms;

R (4) is a hydrogen atom, an alkyl having 1, 2, 3, 4, 5, or 6 carbon atoms or CF ₃ ;

or

R (3) and R (4)

together they are a chain of 4 or 5 methylene groups, of which one methylene group may be substituted by —O—, —S—, —NH—, —N (methyl) - or —N (benzyl) -;

R (5) each independently is F, Cl, Br, I, CF ₃ , NO ₂ , CN, COOMe, CONH ₂ , COMe, NH ₂ , OH, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, methylsulfonyl or methylsulfonylamino, where in the case where a number of radicals A1-A8 are defined as CR (5), the radicals R (5) are each independently determined;

R (30) and R (31),

each independently are a hydrogen atom

or alkyl having 1, 2 or 3 carbon atoms;

or

R (30) and R (31)

together are an oxygen atom or a chain of 2 methylene groups;

and / or compounds of the formula Ie or If

in which

X are an oxygen atom or a sulfur atom;

R (1) are C (O) OR (9), SO ₂ R (10), COR (11), C (O) NR (12) R (13) or C (S) NR (12) R ( 13);

R (9), R (10), R (11) and R (12),

each independently, represent C _x H _2x -R (14);

x is 0, 1, 2, 3 or 4;

where x cannot be 0 when R (14) is OR (15) or SO ₂ Me;

R (14) is alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, cycloalkyl having 3, 4, 5, 6, 7, 8, 9, 10 or 11 carbon atoms, CF ₃ , C ₂ F ₅ , C ₃ F ₇ , CH ₂ F, CHF ₂ , OR (15), SO ₂ Me, phenyl, naphthyl, biphenylyl, furyl, thienyl or an N-containing aromatic heterocycle having 1, 2, 3, 4, 5 6, 7, 8 or 9 carbon atoms,

where phenyl, naphthyl, biphenylyl, furyl, thienyl and an N-containing aromatic heterocycle are unsubstituted or substituted by 1, 2 or 3 substituents selected from the group consisting of F, Cl, Br, I, CF ₃ , OCF ₃ , NO ₂ , CN, COOMe, CONH ₂ , COMe, NH ₂ , OH, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino;

R (15) is alkyl having 1, 2, 3, 4 or 5 carbon atoms, cycloalkyl having 3, 4, 5 or 6 carbon atoms, CF ₃ or phenyl, which is unsubstituted or substituted with 1, 2 or 3 substituents, selected from the group consisting of F, Cl, Br, I, CF ₃ , NO ₂ , CN, COOMe, CONH ₂ , COMe, NH ₂ , OH, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino;

R (13) is a hydrogen atom, an alkyl having 1, 2, 3 or 4 carbon atoms or CF ₃ ;

R (2) is a hydrogen atom, an alkyl having 1, 2, 3 or 4 carbon atoms or CF ₃ ;

R (3) is C _y H _2y —R (16);

y takes values 0, 1, 2, 3 or 4,

where y cannot be 0 when R (16) is OR (17) or SO ₂ Me;

R (16) is alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, cycloalkyl having 3, 4, 5, 6, 7, 8, 9, 10 or 11 carbon atoms, CF ₃ , C ₂ F ₅ , C ₃ F ₇ , CH ₂ F, CHF ₂ , OR (17), SO ₂ Me, phenyl, naphthyl, furyl, thienyl or an N-containing aromatic heterocycle having 1, 2, 3, 4, 5, 6 , 7, 8 or 9 carbon atoms,

where phenyl, naphthyl, furyl, thienyl and an N-containing aromatic heterocycle are unsubstituted or substituted with 1, 2 or 3 substituents selected from the group consisting of F, Cl, Br, I, CF ₃ , OCF ₃ , NO ₂ , CN, COOMe, CONH ₂ , COMe, NH ₂ , OH, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino,

R (17) is a hydrogen atom, alkyl having 1, 2, 3, 4 or 5 carbon atoms, cycloalkyl having 3, 4, 5 or 6 carbon atoms, CF ₃ , phenyl or 2-, 3- or 4-pyridyl ,

where phenyl or 2-, 3- or 4-pyridyl are unsubstituted or substituted by 1, 2 or 3 substituents selected from the group consisting of F, Cl, Br, I, CF ₃ , OCF ₃ , NO ₂ , CN, COOMe, CONH ₂ , COMe, NH ₂ , OH, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino;

or

R (3) is CHR (18) R (19);

R (18) is a hydrogen atom or C _z H _2z —R (16), where R (16) is as defined above;

z is 0, 1, 2 or 3;

R (19) is COOH, CONH ₂ , CONR (20) R (21), COOR (22) or CH ₂ OH;

R (20) is a hydrogen atom, an alkyl having 1, 2, 3, 4 or 5 carbon atoms, C _v H _2v —CF ₃ or C _w H _{2w —} phenyl,

where the phenyl ring is unsubstituted or substituted by 1, 2 or 3 substituents selected from the group consisting of F, Cl, Br, I, CF ₃ , NO ₂ , CN, COOMe, CONH ₂ , COMe, NH ₂ , OH, alkyl, having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino;

v takes values 0, 1, 2 or 3;

w takes values 0, 1, 2 or 3;

R (21) is a hydrogen atom or an alkyl having 1, 2, 3, 4 or 5 carbon atoms;

R (22) is an alkyl having 1, 2, 3, 4 or 5 carbon atoms;

R (4) is a hydrogen atom, an alkyl having 1, 2, 3, 4, 5, or 6 carbon atoms or CF ₃ ;

or

R (3) and R (4)

together they are a chain of 4 or 5 methylene groups, of which one methylene group may be substituted by —O—, —S—, —NH—, —N (methyl) - or —N (benzyl) -;

R (5), R (6) and R (7),

each independently, is a hydrogen atom, F, Cl, Br, I, CF ₃ , NO ₂ , CN, COOMe, CONH ₂ , COMe, NH ₂ , OH, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy, having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, methylsulfonyl or methylsulfonylamino;

R (30) and R (31),

each independently, is a hydrogen atom or an alkyl having 1, 2 or 3 carbon atoms;

or

R (30) and R (31)

together are an oxygen atom or a chain of 2 methylene groups;

and / or compounds of the formula Ig

wherein

R (1) is (CH ₂ ) _X -R (8)

x takes values 0, 1, 2, 3, 4 or 5,

R (8) represents phenyl, thienyl or furanyl,

where phenyl, thienyl and furanyl are unsubstituted or substituted by 1, 2 or 3 substituents selected from the group consisting of F, Cl, Br, I, CF ₃ , OCF ₃ , NO ₂ , CN, COOMe, CONH ₂ , COMe, NH ₂ , OH, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino;

R (2) is a hydrogen atom or an alkyl having 1, 2 or 3 carbon atoms;

R (3) is a hydrogen atom or an alkyl having 1, 2 or 3 carbon atoms;

R (4) is alkyl having 3, 4, 5, 6 or 7 carbon atoms, cycloalkyl having 3, 4, 5, 6 or 7 carbon atoms, phenyl, naphthyl or heteroaryl,

where phenyl and heteroaryl are unsubstituted or substituted by 1, 2 or 3 substituents selected from the group consisting of F, Cl, Br, I, CF ₃ , OCF ₃ , NO ₂ , COOMe, CONH ₂ , COMe, NH ₂ , OH, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, dimethylamino, methylsulfonyl and methylsulfonylamino;

R (5), R (6) and R (7),

each independently, are F, Cl, Br, I, CF ₃ , OCF ₃ , NO ₂ , CN, COOMe, CONH ₂ , COMe, OH, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino;

and / or compounds of formula Ih

wherein

A is —C _n H _2n -;

n is 0, 1, 2, 3, 4 or 5;

O represents an oxygen atom;

D is a bond or an oxygen atom;

E is —C _m H _2m -;

m is 0, 1, 2, 3, 4 or 5;

R (8) is a hydrogen atom, alkyl having 1, 2, 3 or 4 carbon atoms or C _p H _2p -R (14);

p is 0, 1, 2, 3, 4 or 5;

R (14) is cycloalkyl having 3, 4, 5 or 6 carbon atoms, aryl or heteroaryl, where aryl and heteroaryl are each unsubstituted or substituted with 1, 2 or 3 substituents selected from the group consisting of F, Cl, Br , I, CF ₃ , OCF ₃ , NO ₂ , CN, COOMe, CONH ₂ , COMe, NH ₂ , OH, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 atoms carbon, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino;

R (9) is a hydrogen atom or an alkyl having 1, 2, 3, 4, 5, or 6 carbon atoms;

R (10) is a hydrogen atom, alkyl having 1, 2, 3 or 4 carbon atoms, cycloalkyl having 3, 4, 5 or 6 carbon atoms, aryl or heteroaryl,

where aryl and heteroaryl are each unsubstituted or substituted with 1, 2 or 3 substituents selected from the group consisting of F, Cl, Br, I, CF ₃ , OCF ₃ , NO ₂ , CN, COOMe, CONH ₂ , COMe, NH ₂ , OH, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino;

R (11) is cycloalkyl having 3, 4, 5 or 6 carbon atoms, phenyl, naphthyl, thienyl, furyl, pyridyl, pyrazinyl, pyridazinyl or pyrimidyl,

where phenyl, naphthyl, thienyl, furyl, pyridyl, pyrazinyl, pyridazinyl and pyrimidyl are each unsubstituted or substituted with 1, 2 or 3 substituents selected from the group consisting of F, Cl, Br, I, CF ₃ , OCF ₃ , NO ₂ , CN, COMe, NH ₂ , OH, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino;

R (12) is alkyl having 1, 2, 3 or 4 carbon atoms, cycloalkyl having 3, 4, 5 or 6 carbon atoms, aryl or heteroaryl,

where each aryl and heteroaryl is unsubstituted or substituted by 1, 2 or 3 substituents selected from the group consisting of F, Cl, Br, I, CF ₃ , OCF ₃ , NO ₂ , CN, COOMe, CONH ₂ , COMe, NH ₂ , OH, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino;

R (13) is C _p H _2p -R (14 ');

p is 0, 1, 2, 3, 4 or 5;

R (14 ') is cycloalkyl having 3, 4, 5 or 6 carbon atoms, tetrahydrofuranyl, tetrahydropyranyl, aryl or heteroaryl,

where each aryl and heteroaryl is unsubstituted or substituted by 1, 2 or 3 substituents selected from the group consisting of F, Cl, Br, I, CF ₃ , OCF ₃ , NO ₂ , CN, COOMe, CONH ₂ , COMe, NH ₂ , OH, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino;

R (15) is cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms;

R (2) is a hydrogen atom or an alkyl having 1, 2, 3 or 4 carbon atoms;

R (3) is alkyl having 3, 4, 5, 6, or 7 carbon atoms, cycloalkyl having 3, 4, 5, or 6 carbon atoms, phenyl or naphthyl,

where each phenyl or naphthyl is unsubstituted or substituted with 1, 2 or 3 substituents selected from the group consisting of F, Cl, Br, I, CF ₃ , OCF ₃ , NO ₂ , CN, COOMe, CONH ₂ , COMe, NH ₂ , OH, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino;

R (4), R (5), R (6) and R (7),

each independently a hydrogen atom, F, Cl, Br, I, CF ₃ , OCF ₃ , OCHF ₂ , NO ₂ , CN, COOMe, CONH ₂ , COMe, NH ₂ , OH, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino;

and / or compounds of formula Ij

wherein

A is —C _n H _2n -;

n is 0, 1, 2, 3, 4 or 5;

D is a bond or —O—;

E is —C _m H _2m -;

m is 0, 1, 2, 3, 4 or 5;

R (8) is a hydrogen atom, alkyl having 1, 2, 3 or 4 carbon atoms or C _p H _2p -R (14);

p is 0, 1, 2, 3, 4 or 5;

R (14) is phenyl, naphthyl or heteroaryl,

where each phenyl, naphthyl and heteroaryl is unsubstituted or substituted with 1, 2 or 3 substituents selected from the group consisting of F, Cl, Br, I, CF ₃ , OCF ₃ , NO ₂ , CN, COOMe, CONH ₂ , COMe, NH ₂ , OH, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino;

R (9) is a hydrogen atom or an alkyl having 1, 2, 3, 4, 5, or 6 carbon atoms;

R (10) is a hydrogen atom, an alkyl having 1, 2, 3 or 4 carbon atoms, phenyl, naphthyl or heteroaryl,

where each phenyl, naphthyl and heteroaryl is unsubstituted or substituted with 1, 2 or 3 substituents selected from the group consisting of F, Cl, Br, I, CF ₃ , OCF ₃ , NO ₂ , CN, COOMe, CONH ₂ , COMe, NH ₂ , OH, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino;

R (11) is cycloalkyl having 3, 4, 5, or 6 carbon atoms, phenyl, naphthyl, thienyl, furyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolyl, indazolyl, quinolyl, isoquinolyl, phthalazinyl, quinoline, quinoxynilinyl, quinoxynilinyl, quinoxynilinyl, quinoline, quinoline,

where each phenyl, naphthyl, thienyl, furyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolyl, indazolyl, quinolyl, isoquinolyl, phthalazinyl, quinoxalinyl, quinazolinyl or cinnolinyl is unsubstituted or substituted with 1, 2 or 3 substituents F, Cl, Br, I, CF ₃ , OCF ₃ , NO ₂ , CN, COMe, NH ₂ , OH, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms , dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino;

R (12) is alkyl having 1, 2, 3 or 4 carbon atoms, alkynyl having 1, 2, 3 or 4 carbon atoms, cycloalkyl having 3, 4, 5 or 6 carbon atoms, phenyl, naphthyl or heteroaryl,

where each phenyl, naphthyl and heteroaryl is unsubstituted or substituted with 1, 2 or 3 substituents selected from the group consisting of F, Cl, Br, I, CF ₃ , OCF ₃ , NO ₂ , CN, COOMe, CONH ₂ , COMe, NH ₂ , OH, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino;

R (13) is C _p H _2p -R (14);

p is 0, 1, 2, 3, 4 or 5;

R (15) is cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms;

R (2) is a hydrogen atom or an alkyl having 1, 2, 3 or 4 carbon atoms;

R (3) is heteroaryl,

where heteroaryl is unsubstituted or substituted by 1, 2 or 3 substituents selected from the group consisting of F, Cl, Br, I, CF ₃ , OCF ₃ , NO ₂ , CN, COOMe, CONH ₂ , COMe, NH ₂ , OH, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino;

R (4), R (5), R (6) and R (7),

each independently a hydrogen atom, F, Cl, Br, I, CF ₃ , OCF ₃ , NO ₂ , CN, COOMe, CONH ₂ , COMe, NH ₂ , OH, alkyl having 1, 2, 3 or 4 carbon atoms alkoxy having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino;

and / or physiologically compatible salts of the compounds of formulas Ia, Ib, Ic, Id, Ie, If, Ig, Ih or Ij for the manufacture of a medicament for the treatment or prevention of respiratory disorders, respiratory disorders in sleep, attacks of central and obstructive sleep apnea, syndrome impaired patency of the upper respiratory tract, Cheyne-Stokes respiration, snoring, impaired central regulation of respiration, sudden infant death, postoperative hypoxia and apnea; muscle respiratory disorders, respiratory disorders after prolonged ventilation, respiratory disorders during adaptation in high mountains, acute and chronic pulmonary disorders with hypoxia and hypercapnia; neurodegenerative disorders, dementia, Alzheimer's disease, Parkinson's disease, Huntington's disease; cancer, breast cancer, lung cancer, colon cancer, and prostate cancer.

Preference is given to the use of the compounds of formulas Ia-Ij and / or their physiologically compatible salts in the preparation of a medicament for the treatment or prophylaxis of respiratory disorders, in particular sleep apnea, cancer.

The use of compounds of formulas Ia-Ij and / or their physiologically compatible salts is to provide a medicament for the treatment or prevention of respiratory disorders, in particular respiratory disorders in sleep, such as attacks of central and obstructive sleep apnea, upper respiratory tract obstruction syndrome, Cheyne-Stokes breathing, snoring, impaired central regulation of breathing (sudden infant death, postoperative hypoxia and apnea), muscle respiratory disorders, respiratory distress properties after prolonged ventilation of the lungs, respiratory disorders during adaptation in high mountains, acute and chronic pulmonary disorders with hypoxia and hypercapnia.

Further use of the compounds of formula Ia-Ij and / or their physiologically compatible salts is to provide a medicament for the treatment or prevention of respiratory disorders, in particular respiratory disorders in sleep, such as attacks of central and obstructive sleep apnea, Chain-Stokes breathing, snoring, violation of the central regulation of breathing (sudden infant death, postoperative hypoxia and apnea), muscle respiratory disorders, respiratory disorders after prolonged ventilation, respiration Athorne disorders during adaptation in high mountains, acute and chronic pulmonary disorders with hypoxia and hypercapnia.

A preferred use of the compounds of formulas Ia-Ij and / or their physiologically compatible salts is to provide a medicament for the treatment or prevention of sleep respiratory disorders, such as attacks of central and obstructive sleep apnea, upper respiratory tract obstruction syndrome, and snoring.

Another preferred use of the compounds of formulas Ia-Ij and / or their physiologically compatible salts is in the manufacture of a medicament for the treatment or prevention of sleep apnea, for example, central and obstructive sleep apnea and snoring.

A further use of the compounds of formulas Ia-Ij and / or their physiologically compatible salt is to provide a medicament for the treatment or prophylaxis of neurodegenerative disorders such as dementia, Alzheimer's disease, Parkinson's disease, Huntington's disease.

A further use of the compounds of formulas Ia-Ij and / or their physiologically compatible salt is in the manufacture of a medicament for the treatment or prophylaxis of cancers, for example, breast cancer, lung cancer, colon cancer and prostate cancer.

In one embodiment of the invention, the compounds of formulas Ia-Ij are used to produce an intravenous drug, in particular to provide an intravenous drug for the treatment or prevention of respiratory disorders, preferably sleep respiratory disorders, such as central and obstructive sleep apnea in a dream, a syndrome of impaired patency of the upper respiratory tract and snoring, for example, such respiratory disorders in a dream as attacks of the central and tive sleep apnea and snoring.

In a further embodiment of the invention, the compounds of formulas Ia-Ij are used to prepare a medicament for oral administration; in particular, to provide a medicament for oral administration in the treatment or prophylaxis of respiratory disorders, preferably sleep respiratory disorders, such as central and obstructive sleep apnea attacks, upper respiratory tract obstruction syndrome and snoring, for example, respiratory sleep disorders, such as bouts of central and obstructive sleep apnea and snoring.

In a further embodiment of the invention, the compounds of formulas Ia-Ij are used to prepare a medicament for nasal administration, in particular to obtain a medicament for nasal administration in the treatment or prevention of respiratory disorders; preferably respiratory disorders in sleep, such as attacks of obstructive sleep apnea, syndrome of impaired patency of the upper respiratory tract and snoring, for example, such respiratory disorders in sleep, such as attacks of obstructive sleep apnea and snoring.

In one embodiment of the invention, compounds of formula Ia are used in which

R (1) is a hydrogen atom;

R (2) is R (20) —C _r H _2r ;

R (20) represents CH ₃ , CH ₂ F, CHF ₂ , CF ₃ , cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms, —CONR (22) R (23), —OR (24 ), -COOR (24) or phenyl, which is unsubstituted or substituted by 1 or 2 substituents selected from the group consisting of F, Cl, Br, CF ₃ , NO ₂ , CN, OH, methyl, ethyl, hydroxymethyl, hydroxyethyl, methoxy, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino;

R (22) and R (23),

each independently, is a hydrogen atom or an alkyl having 1, 2, 3 or 4 carbon atoms;

or

R (22) and (R (23)

together represents a chain of 4 or 5 methylene groups, of which one CH ₂ group may be substituted by —O—, —S—, —NH—, —N (methyl) - or —N (benzyl) -;

R (24) is a hydrogen atom or an alkyl having 1, 2 or 3 carbon atoms;

r takes the values zero, 1, 2, 3, 4 or 5;

R (3), R (4), R (5) and R (6),

each independently, is a hydrogen atom, F, Cl, Br, I, alkyl having 1, 2, 3, 4 or 5 carbon atoms, cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms, CN, CF ₃ , NO ₂ or OR (25);

R (25) is a hydrogen atom, alkyl having 1, 2, 3 or 4 carbon atoms, a fluorinated alkyl radical of the formula —C _x H _2x CF _y H _3-y, or phenyl which is unsubstituted or substituted with 1 or 2 substituents selected from the group consisting of F, Cl, Br, CF ₃ , NO ₂ , CN, OH, methyl, ethyl, methoxy, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino;

x is 0, 1, 2, or 3;

y takes values 1, 2 or 3;

R (7) is a hydrogen atom or an alkyl having 1, 2, 3 or 4 carbon atoms;

R (8) is a 1-indanyl radical of formula II;

R (9) is a hydrogen atom or OR (28);

R (28) is a hydrogen atom or an alkyl having 1, 2, 3 or 4 carbon atoms;

R (10) and R (11),

each independently, is a hydrogen atom or an alkyl having 1, 2, 3 or 4 carbon atoms;

R (12), R (13), R (14) and R (15),

each independently, is a hydrogen atom, F, Cl, Br, I, alkyl having 1, 2, 3, 4 or 5 carbon atoms, cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms, CN, CF ₃ , -NO ₂ or -YC _s H _2s -R (29);

Y represents -O-, -CO-, -CO-O-, -O-CO-, -S-, -SO-, -SO ₂ -, -O-SO ₂ -, -SO ₂ NR (30) -, -CONR (30) - or -NR (30) CO-, where the bond with the main structure in each case is through an atom located on the left;

R (30) is a hydrogen atom or an alkyl having 1, 2 or 3 carbon atoms;

s is zero, 1, 2, 3, 4, or 5;

R (29) is a hydrogen atom, methyl, CF ₃ , -OR (31), -COOR {31), -NR (32) R (33), -CONR (32) R (33) or phenyl,

which is unsubstituted or substituted by 1 or 2 substituents selected from the group consisting of F, Cl, Br, CF ₃ , NO ₂ , CN, OH, methyl, ethyl, methoxy, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino;

R (31) is a hydrogen atom or an alkyl having 1, 2 or 3 carbon atoms;

R (32) and R (33),

each independently, is a hydrogen atom or an alkyl having 1, 2, 3 or 4 carbon atoms;

or

R (32) and R (33)

together represents a chain of 4 or 5 methylene groups, of which one CH ₂ group may be substituted by —O—, —S—, —NH—, —N (CH ₃ ) - or —N (benzyl) -;

and / or compounds of formula Ib, in which

R (1) represents C (O) OR (9), SO ₂ R (10), COR (11) or C (O) NR (12) R (13);

R (9) is C _x H _2x -R (14);

x takes values 0, 1, 2, 3 or 4,

where x cannot be 0 when R (14) is OR (15);

R (14) is alkyl having 1, 2, 3 or 4 carbon atoms, cycloalkyl having 3, 4, 5, 6, 7, 8 or 9 carbon atoms, CF ₃ , C ₂ F ₅ , OR (15), phenyl, furyl, thienyl or an N-containing aromatic heterocycle having 1, 2, 3, 4, 5, 6, 7, 8 or 9 carbon atoms,

where phenyl, furyl, thienyl and an N-containing aromatic heterocycle are each unsubstituted or substituted with 1, 2 or 3 substituents selected from the group consisting of F, Cl, Br, CF ₃ , OCF ₃ , NO ₂ , CN, COOMe , CONH ₂ , COMe, NH ₂ , OH, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino;

R (15) is alkyl having 1, 2, 3, 4 or 5 carbon atoms, cycloalkyl having 3, 4, 5 or 6 carbon atoms, CF ₃ or phenyl, which is unsubstituted or substituted with 1, 2 or 3 substituents, selected from the group consisting of F, Cl, Br, CF ₃ , NO ₂ , CN, COOMe, CONH ₂ , COMe, OH, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino;

R (10), R (11) and R (12),

each independently determined analogously to R (9);

R (13) is a hydrogen atom, an alkyl having 1, 2, 3 or 4 carbon atoms or CF ₃ ;

R (2) is a hydrogen atom, an alkyl having 1, 2, 3 or 4 carbon atoms or CF ₃ ;

R (3) is C _y H _2y —R (16);

y takes values 0, 1, 2, 3 or 4,

where y cannot be 0 when R (16) is OR (17);

R (16) is alkyl having 1, 2, 3 or 4 carbon atoms, cycloalkyl having 3, 4, 5, 6, 7, 8 or 9 carbon atoms, CF ₃ , C ₂ F ₅ , OR (17), phenyl, furyl, thienyl or an N-containing aromatic heterocycle having 1, 2, 3, 4, 5, 6, 7, 8 or 9 carbon atoms,

where phenyl, furyl, thienyl and an N-containing aromatic heterocycle are each unsubstituted or substituted with 1, 2 or 3 substituents selected from the group consisting of F, Cl, Br, CF ₃ , OCF ₃ , NO ₂ , CN, COOMe , CONH ₂ , COMe, NH ₂ , OH, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino;

R (17) is alkyl having 1, 2, 3, 4 or 5 carbon atoms, cycloalkyl having 3, 4, 5 or 6 carbon atoms, CF ₃ , phenyl or 2-, 3- or 4-pyridyl,

where phenyl or 2-, 3- or 4-pyridyl are unsubstituted or substituted with 1, 2 or 3 substituents selected from the group consisting of F, Cl, Br, CF ₃ , OCF ₃ , NO ₂ , CN, COOMe, CONH ₂ , COMe, OH, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino;

or

R (3) is CHR (18) R (19);

R (18) is a hydrogen atom or C _z H _2z -R (16), where R (16) is defined above

z is 0, 1, 2 or 3;

R (19) is CONH ₂ , CONR (20) R (21), COOR (22), CH ₂ OH;

R (20) is a hydrogen atom, an alkyl having 1, 2, 3, 4 or 5 carbon atoms, C _v H _2v —CF ₃ or C _w H _{2w —} phenyl,

where the phenyl ring is unsubstituted or substituted by 1, 2 or 3 substituents selected from the group consisting of F, Cl, Br, CF ₃ , OCF ₃ , NO ₂ , CN, COOMe, CONH ₂ , COMe, NH ₂ , OH, alkyl, having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino,

v takes values 0, 1, 2 or 3;

w takes values 0, 1, 2 or 3;

R (21) is a hydrogen atom or an alkyl having 1, 2, 3, 4 or 5 carbon atoms;

R (22) is an alkyl having 1, 2, 3, 4 or 5 carbon atoms;

R (4) is a hydrogen atom, an alkyl having 1, 2, 3, 4, 5, or 6 carbon atoms or CF ₃ ;

R (5), R (6), R (7) and R (8),

each independently, is a hydrogen atom, F, Cl, Br, CF ₃ , NO ₂ , CN, COOMe, CONH ₂ , COMe, NH ₂ , OH, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1 , 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, methylsulfonyl or methylsulfonylamino;

R (30) and R (31),

each independently is a hydrogen atom or an alkyl having 1, 2 or 3 carbon atoms;

or

R (30) and R (31)

together represent a chain of two methylene groups;

and / or compounds of formula Ic in which

A1, A2, A3, A4, A5, A6, A7 and A8,

each independently, is a nitrogen atom, CH or CR (5), where at most one of these groups is a nitrogen atom and at least 5 of these groups are CH;

R (1) are C (O) OR (9), SO ₂ R (10), COR (11) or C (O) NR (12) R (13);

R (9), R (10), R (11) and R (12),

each independently, is C _x H _2x -R (14);

x is 0, 1, 2, 3 or 4;

R (14)

is alkyl having 1, 2, 3 or 4 carbon atoms, cycloalkyl having 3, 4, 5, 6, 7, 8 or 9 carbon atoms, CF ₃ , phenyl, naphthyl, biphenylyl, furyl, thienyl, or N-containing aromatic a heterocycle having 1, 2, 3, 4, 5, 6, 7, 8 or 9 carbon atoms,

where phenyl, naphthyl, biphenylyl, furyl, thienyl and an N-containing aromatic heterocycle are each unsubstituted or substituted with 1, 2 or 3 substituents selected from the group consisting of F, Cl, Br, I, CF ₃ , OCF ₃ , NO ₂ , CN, COOMe, CONH ₂ , COMe, NH ₃ , OH, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino ;

R (13) is a hydrogen atom;

R (2) is a hydrogen atom or methyl;

R (3) is C _y H _2y —R (16);

y takes the values 0, 1, 2, 3 or 4;

where y cannot be 0 when R (16) is OR (17);

R (16) is alkyl having 1, 2, 3, 4, 5, or 6 carbon atoms, cycloalkyl having 3, 4, 5, 6, 7, 8, or 9 carbon atoms, CF ₃ , OR (17), SO ₂ Me, phenyl, naphthyl, furyl, thienyl or an N-containing aromatic heterocycle having 1, 2, 3, 4, 5, 6, 7, 8 or 9 carbon atoms,

where phenyl, naphthyl, furyl, thienyl and an N-containing aromatic heterocycle are each unsubstituted or substituted with 1, 2 or 3 substituents selected from the group consisting of F, Cl, Br, I, CF ₃ , NO ₂ , OCF ₃ , CN, COOMe, CONH ₂ , COMe, NH ₂ , OH, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino;

R (17) is a hydrogen atom, alkyl having 1, 2, 3, 4 or 5 carbon atoms, cycloalkyl having 3, 4, 5 or 6 carbon atoms, CF ₃ , phenyl or 2-, 3- or 4-pyridyl ,

where phenyl or 2-, 3- or 4-pyridyl each is unsubstituted or substituted with 1, 2 or 3 substituents selected from the group consisting of F, Cl, Br, I, CF ₃ , NO ₂ , CN, COOMe, CONH ₂ , COMe, NH ₂ , OH, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino;

R (4) is a hydrogen atom, an alkyl having 1 or 2 carbon atoms;

R (5) is F, Cl, Br, I, CF ₃ , NO ₂ , CN, COOMe, CONH ₂ , COMe, NH ₂ , OH, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1 , 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino;

R (30) and R (31),

each independently a hydrogen atom or methyl;

and / or compounds of formula (Id) in which

A1, A2, A3, A4, A5, A6, A7 and A8, each independently, is a nitrogen atom, CH or CR (5), where at least one of these groups and at most two of these groups are a nitrogen atom and at least four of these groups are CH;

R (1) is C (O) OR (9), SO ₂ R (10), COR (11) or C (O) NR (12) R (13)

R (9), R (10), R (11) and R (12),

each independently, is C _x H _2x -R (14);

x is 0, 1, 2, 3 or 4;

where x cannot be 0 when R (14) is OR (15);

R (14) is alkyl having 1, 2, 3 or 4 carbon atoms, cycloalkyl having 3, 4, 5, 6, 7, 8 or 9 carbon atoms, CF ₃ , OR (15), phenyl, naphthyl, biphenylyl , furyl, thienyl or an N-containing aromatic heterocycle having 1, 2, 3, 4, 5, 6, 7, 8 or 9 carbon atoms,

where each phenyl, naphthyl, biphenylyl, furyl, thienyl and N-containing aromatic heterocycle is unsubstituted or substituted by 1, 2 or 3 substituents selected from the group consisting of F, Cl, Br, I, CF ₃ , OCF ₃ , NO ₂ , CN, COOMe, CONH ₂ , COMe, NH ₂ , OH, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino;

R (15) is alkyl having 1, 2, 3, 4 or 5 carbon atoms, cycloalkyl having 3, 4, 5 or 6 carbon atoms, CF ₃ or phenyl, which is unsubstituted or substituted with 1, 2 or 3 substituents, selected from the group consisting of F, Cl, Br, I, CF ₃ , NO ₂ , CN, COOMe, CONH ₂ , COMe, NH ₂ , OH, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino;

R (13) is a hydrogen atom, an alkyl having 1, 2, 3 or 4 carbon atoms or CF ₃ ;

R (2) is a hydrogen atom, an alkyl having 1, 2, 3 or 4 carbon atoms or CF ₃ ;

R (3) is C _y H _2y —R (16);

y takes values 0, 1, 2, 3 or 4,

where y cannot be 0 when R (16) is OR (17) or SO ₂ Me;

R (16) is, alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, cycloalkyl having 3, 4, 5, 6, 7, 8 or 9 carbon atoms, CF ₃ , OR (17), SO ₂ Me, phenyl, naphthyl, furyl, thienyl or an N-containing aromatic heterocycle having 1, 2, 3, 4, 5, 6, 7, 8 or 9 carbon atoms,

where each phenyl, naphthyl, furyl, thienyl and N-containing aromatic heterocycle are unsubstituted or substituted by 1, 2 or 3 substituents selected from the group consisting of F, Cl, Br, I, CF ₃ , OCF ₃ , NO ₂ , CN , COOMe, CONH ₂ , COMe, NH ₂ , OH, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino;

R (17) is a hydrogen atom, alkyl having 1, 2, 3, 4 or 5 carbon atoms, cycloalkyl having 3, 4, 5 or 6 carbon atoms, CF ₃ , phenyl or 2-, 3- or 4-pyridyl where each phenyl or 2-, 3- or 4-pyridyl is unsubstituted or substituted with 1, 2 or 3 substituents selected from the group consisting of F, Cl, Br, I, CF ₃ , OCF ₃ , NO ₂ , CN, COOMe, CONH ₂ , COMe, NH ₂ , OH, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino;

or

R (3) is CHR (18) R (19);

R (18) is a hydrogen atom or C _z H _2z —R (16), where R (16) is as defined above;

z is 0, 1, 2 or 3;

R (19) is CONH ₂ , CONR (20) R (21), COOR (22) or CH ₂ OH;

R (20) is a hydrogen atom, an alkyl having 1, 2, 3, 4 or 5 carbon atoms, C _v H _2v —CF ₃ or C _w H _{2w —} phenyl,

where the phenyl ring is unsubstituted or substituted by 1, 2 or 3 substituents selected from the group consisting of F, Cl, Br, I, CF ₃ , OCF ₃ , NO ₂ , CN, COOMe, CONH ₂ , COMe, NH ₂ , OH alkyl, having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino;

v takes values 0, 1, 2 or 3;

w takes values 0, 1, 2 or 3;

R (21) is a hydrogen atom or an alkyl having 1, 2, 3, 4 or 5 carbon atoms;

R (22) is an alkyl having 1, 2, 3, 4 or 5 carbon atoms;

R (4) is a hydrogen atom, an alkyl having 1, 2, 3, 4, 5, or 6 carbon atoms or CF ₃ ;

R (5) each independently is F, Cl, Br, I, CF ₃ , NO ₂ , CN, COOMe, CONH ₂ , COMe, NH ₂ , OH, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, methylsulfonyl or methylsulfonylamino;

R (30) and R (31),

each independently is a hydrogen atom or an alkyl having 1, 2 or 3 carbon atoms;

or

R (30) and R (31)

or represent a chain of 2 methylene groups;

and / or a compound of formula Ie or If in which

X is an oxygen atom or a sulfur atom;

R (1) is C (O) OR (9) or COR (11);

R (9) and R (11),

each independently, is C _x H _2x -R (14);

x is 0, 1, 2, or 3;

R (14) is cycloalkyl having 5 or 6 carbon atoms or phenyl, where phenyl is unsubstituted or substituted with 1 or 2 substituents selected from the group consisting of F, Cl, Br, I, CF ₃ , OCF ₃ , OH, alkyl having 1, 2 or 3 carbon atoms or alkoxy, having 1 or 2 carbon atoms;

R (2) is a hydrogen atom;

R (3) is C _y H _2y —R (16);

y takes the values 0, 1 or 2;

R (16) is alkyl having 1, 2 or 3 carbon atoms, cycloalkyl having 5 or 6 carbon atoms, phenyl or pyridyl,

where each phenyl and pyridyl is unsubstituted or substituted with 1, 2 or 3 substituents selected from the group consisting of F, Cl, CF ₃ , alkyl having 1, 2 or 3 carbon atoms, and alkoxy having 1 or 2 carbon atoms ;

R (4) is a hydrogen atom;

R (5) R (6) and R (7)

each independently, is a hydrogen atom, F, Cl, alkyl having 1, 2 or 3 carbon atoms, or alkoxy having 1 or 2 carbon atoms;

R (30) and R (31),

each is a hydrogen atom;

and / or compounds of the formula Ig, in which

R (1) is (CH ₃ ) _X -R (8),

x takes values 1 or 2;

R (8) is phenyl, thienyl or furanyl,

where each phenyl, thienyl and furanyl is unsubstituted or substituted by 1, 2 or 3 substituents selected from the group consisting of F, Cl, Br, CF ₃ , OCF ₃ , CN, COOMe, CONH ₂ , COMe, alkyl having 1, 2 or 3 carbon atoms, alkoxy having 1, 2 or 3 carbon atoms, sulfamoyl, methylsulfonyl and methylsulfonylamino;

R (2) is a hydrogen atom or an alkyl having 1 or 2 carbon atoms;

R (3) is a hydrogen atom;

R (4) is phenyl,

where phenyl is unsubstituted or substituted by 1, 2 or 3 substituents selected from the group consisting of F, Cl, Br, CF ₃ , OCF ₃ , COMe, alkyl having 1, 2 or 3 carbon atoms, and alkoxy having 1, 2 or 3 carbon atoms;

R (5) R (6) and R (7)

each independently, is F, Cl, Br, CF ₃ , OCF ₃ , CN, COOMe, CONH ₂ , COMe, alkyl having 1, 2 or 3 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, dimethylamino sulfamoyl, methylsulfonyl and methylsulfonylamino;

and / or compounds of formula Ih, in which

A is —C _n H _2n -;

n is 0, 1, 2 or 3;

O is an oxygen atom;

D is a bond or an oxygen atom;

E is —C _m H _2m -;

m is 0, 1, 2 or 3;

R (8) is a hydrogen atom or an alkyl having 1, 2, 3 or 4 carbon atoms;

R (9) is a hydrogen atom or an alkyl having 1, 2, 3, 4, 5, or 6 carbon atoms;

R (10) is a hydrogen atom, alkyl having 1, 2, 3 or 4 carbon atoms, or cycloalkyl having 3, 4 or 5 carbon atoms,

R (11) is cycloalkyl having 3, 4, 5 or 6 carbon atoms, phenyl or pyridyl,

where each phenyl and pyridyl is unsubstituted or substituted by 1, 2 or 3 substituents selected from the group consisting of F, Cl, Br, CF ₃ , OCF ₃ , NO ₂ , CN, COMe, OH, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino;

R (12) is alkyl having 1, 2, 3 or 4 carbon atoms, cycloalkyl having 3, 4 or 5 carbon atoms, aryl or heteroaryl,

where each aryl and heteroaryl is unsubstituted or substituted by 1, 2 or 3 substituents selected from the group consisting of F, Cl, Br, CF ₃ , OCF ₃ , NO ₂ , CN, COOMe, CONH ₂ , COMe, OH, alkyl, having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino;

R (13) is C _p H _2p -R (14 ');

p is 0, 1, 2, 3, 4 or 5;

R (14 ') is cycloalkyl having 3, 4, 5 or 6 carbon atoms, tetrahydrofuranyl, tetrahydropyranyl, aryl or heteroaryl,

where each aryl and heteroaryl is unsubstituted or substituted by 1, 2 or 3 substituents selected from the group consisting of F, Cl, Br, CF ₃ , OCF ₃ , NO ₂ , CN, COOMe, CONH ₂ , COMe, OH, alkyl, having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino;

R (2) is a hydrogen atom or an alkyl having 1 or 2 carbon atoms;

R (3) is alkyl having 3, 4 or 5 carbon atoms, or phenyl,

where phenyl is unsubstituted or substituted by 1, 2 or 3 substituents selected from the group consisting of F, Cl, Br, CF ₃ , OCF ₃ , NO ₂ , COOMe, CONH ₂ , COMe, OH, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino;

R (4), R (5), R (6) and R (7),

each independently, is a hydrogen atom F, Cl, Br, CF ₃ , OCF ₃ , OCHF ₂ , NO ₂ , CN, COOMe, CONH ₂ , COMe, OH, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy, having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino;

and / or compounds of formula Ij in which

A is —C _n H _2n -;

n = 0, 1, 2, 3, 4 or 5;

D is a bond or —O—;

E is —C _m H _2m -;

m = 0, 1, 2, 3, 4 or 5;

R (8) is a hydrogen atom, an alkyl having 1, 2, 3 or 4 carbon atoms, or C _p H _2p —R (14);

p is 0, 1, 2, 3, 4 or 5;

R (14) is phenyl, naphthyl or heteroaryl,

where each phenyl, naphthyl and heteroaryl is unsubstituted or substituted with 1, 2 or 3 substituents selected from the group consisting of F, Cl, Br, I, CF ₃ , OCF ₃ , NO ₂ , CN, COOMe, CONH ₂ , COMe, NH ₂ , OH, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino;

R (9) is a hydrogen atom or an alkyl having 1, 2, 3, 4, 5, or 6 carbon atoms;

R (10) is a hydrogen atom, an alkyl having 1, 2, 3 or 4 carbon atoms, phenyl, naphthyl or heteroaryl,

where each phenyl, naphthyl and heteroaryl is unsubstituted or substituted with 1, 2 or 3 substituents selected from the group consisting of F, Cl, Br, I, CF ₃ , OCF ₃ , NO ₂ , CN, COOMe, CONH ₂ , COMe, NH ₂ , OH, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino;

R (11) is cycloalkyl having 3, 4, 5, or 6 carbon atoms, phenyl, naphthyl, thienyl, furyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolyl, indazolyl, quinolyl, isoquinolyl, phthalazinyl, quinoline, quinoxynilinyl, quinoxynilinyl, quinoxynilinyl, quinoline, quinoline,

where each phenyl, naphthyl, thienyl, furyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolyl, indazolyl, quinolyl, isoquinolyl, phthalazinyl, quinoxalinyl, quinazolinyl or cinnolinyl is unsubstituted or substituted with 1, 2 or 3 substituents F, Cl, Br, I, CF ₃ , OCF ₃ , NO ₂ , CN, COMe, NH ₂ , OH, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 atoms carbon, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino;

R (12) is alkyl having 1, 2, 3 or 4 carbon atoms, alkynyl having 1, 2, 3 or 4 carbon atoms, cycloalkyl having 3, 4, 5 or 6 carbon atoms, phenyl, naphthyl or heteroaryl,

where each phenyl, naphthyl and heteroaryl is unsubstituted or substituted with 1, 2 or 3 substituents selected from the group consisting of F, Cl, Br, I, CF ₃ , OCF ₃ , NO ₂ , CN, COOMe, CONH ₂ , COMe, NH ₂ , OH, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino;

R (13) is C _p H _2p -R (14);

p is 0, 1, 2, 3, 4 or 5;

R (15) is cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms;

R (2) is a hydrogen atom or an alkyl having 1, 2, 3 or 4 carbon atoms;

R (3) is heteroaryl,

where heteroaryl is unsubstituted or substituted by 1, 2 or 3 substituents selected from the group consisting of F, Cl, Br, I, CF ₃ , OCF ₃ , NO ₂ , CN, COOMe, CONH ₂ , COMe, NH ₂ , OH, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino;

R (4), R (5), R (6) and R (7),

each independently, is a hydrogen atom, F, Cl, Br, I, CF ₃ , OCF ₃ , NO ₂ , CN, COOMe, CONH ₂ , COMe, NH ₃ , OH, alkyl having 1, 2, 3 or 4 carbon atoms alkoxy having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino;

and / or physiologically compatible salts of the compounds of formulas Ia, Ib, Ic, Id, Ie, If, Ig, Ih or Ij.

In a further embodiment, the compounds of formula Ia are used.

In a further embodiment of the invention, compounds of formula Ib are used.

In a further embodiment of the invention, compounds of formula Ic are used.

In a further embodiment of the invention, compounds of formula Id are used.

In a further embodiment of the invention, compounds of formula Ie are used.

In a further embodiment of the invention, compounds of the formula If are used.

In a further embodiment of the invention, compounds of the formula Ig are used.

In a further embodiment, a compound of formula Ih.

In a further embodiment of the invention, compounds of formula Ij are used.

Particular preference is given to the use of compounds of formulas Ia, Ib, Ic, Id, Ie, If, Ih and Ij.

In one embodiment, preference is given to compounds of formula Ia in which R (8) is a 1-indanyl radical of formula II, for example, 1-indanyl of formula II, in which each R9, R10, R11, R12, R13, R14 and R15 is hydrogen atom.

In a further embodiment, preference is given to compounds of formula Ia in which R (1) is a hydrogen atom.

In a further embodiment of the invention, preference is given to compounds of the formula Ia in which R (2) is R (20) —C _r H _2r wherein R (20) is CH ₃ , CH ₂ F, CHF ₂ , CF ₃ , cycloalkyl having 3 , 4, 5, 6, 7 or 8 carbon atoms, —CONR (22) R (23), —OR (24), —COOR (24) or phenyl, which is unsubstituted or substituted with 1 or 2 substituents selected from the group consisting of F, Cl, Br, CF ₃ , NO ₂ , CN, OH, methyl, ethyl, hydroxymethyl, hydroxyethyl, methoxy, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino; and r is zero, 1, 2, 3, 4, or 5; particular preference is given to compounds of formula Ia in which R (2) is R (20) —C _r H _2r , where R (20) is CH ₃ and r is 4.

In a further embodiment, preference is given to compounds of formula Ia in which R (3), R (4), R (5) and R (6) are each independently a hydrogen atom, F, Cl, Br, I, alkyl, having 1, 2, 3, 4 or 5 carbon atoms, cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms, CN, CF ₃ , NO ₂ or OR (25); particular preference is given to compounds of formula Ia in which R (3), R (4), R (5) and R (6) are each independently a hydrogen atom or alkyl having 1, 2 or 3 carbon atoms, for example methyl ; particularly preferred are compounds of formula Ia in which each R (3), R (4) and R (5) is hydrogen and R (6) is methyl.

In a further embodiment of the invention, preference is given to compounds of formula Ia in which R (7) is a hydrogen atom or alkyl having 1, 2, 3 or 4 carbon atoms, for example, a hydrogen atom.

In one embodiment, preference is given to compounds of the formula Ib in which R (1) is C (O) OR (9) or COR (11), where each R (9) and R (11) is C _x H _2x - R (14), where x is 0, 1, 2 or 3, and R (14) is cycloalkyl having 5 or 6 carbon atoms, or phenyl, where phenyl is unsubstituted or substituted by 1 or 2 substituents selected from the group consisting of F, Cl, CF ₃ , OCF ₃ , alkyl having 1, 2 or 3 carbon atoms, and alkoxy having 1 or 2 carbon atoms; particular preference is given to compounds of the formula Ib in which R (1) is C (O) OR (9) or COR (11); where each R (9) and R (11) is C _x H _2x -R (14), where x is 1 or 2, and R (14) is phenyl, where phenyl is unsubstituted or substituted by one substituent selected from the group consisting of alkoxy having 1 or 2 carbon atoms, for example methoxy.

In a further embodiment, preference is given to compounds of the formula Ib in which R (2) is hydrogen.

In a further embodiment of the invention, preference is given to compounds of the formula Ib in which R (3) is C _y H _2y -R (16), where y is 0, 1, 2 or 3, and R (16) is an alkyl having 1 , 2 or 3 carbon atoms, cycloalkyl having 5 or 6 carbon atoms, CF ₃ , OR17, phenyl or pyridyl, where R17 is a hydrogen atom; and where each phenyl and pyridyl are unsubstituted or substituted with 1 or 2 substituents selected from the group consisting of F, Cl, CF ₃ , OCF ₃ , alkyl having 1, 2 or 3 carbon atoms, and alkoxy having 1 or 2 atoms carbon; particular preference is given to compounds of formula Ib in which R (3) is C _y H _2y -R (16), where y is 1, 2 or 3, and R (16) is OR17, phenyl or pyridyl, where R17 is a hydrogen atom, and where phenyl and pyridyl are each unsubstituted or substituted with 2 substituents selected from the group consisting of F and Cl, for example F.

In a further embodiment of the invention, preference is given to compounds of the formula Ib in which R (4) is a hydrogen atom or an alkyl having 1 or 2 carbon atoms, for example hydrogen or methyl.

In a further embodiment, preference is given to compounds of the formula Ib in which R (5), R (6), R (7) and R (8) are each independently hydrogen, F, Cl, CF ₃ , alkyl having 1 , 2 or 3 carbon atoms, or alkoxy having 1 or 2 carbon atoms; particular preference is given to compounds of the formula Ib in which R (5) is hydrogen or Cl and each R (6), R (7) and R (8) is hydrogen.

In a further embodiment, preference is given to compounds of the formula Ib in which each R (30) and R (31) is hydrogen.

In one embodiment of the invention, preference is given to compounds of the formula Ic in which A1, A2, A3, A4, A5, A6, A7 and A8 are each independently a nitrogen atom, CH or CR (5), where at most one of of these groups is a nitrogen atom and at least five of these groups are CH; particular preference is given to compounds of formula 1c in which A1 is CR (5), where R (5) is alkyl having 1, 2 or 3 carbon atoms, for example methyl, and each group is A2, A3, A4, A5, A6, A7 and A8 is CH.

In a further embodiment, preference is given to compounds of the formula Ic in which R (1) is C (O) OR (9) or COR (11); where R (9) and R (11), each independently, are C _x H _2x -R (14), where x is 0, 1, 2 or 3, and R (14) is cycloalkyl having 5 or 6 atoms carbon, or phenyl, where phenyl is unsubstituted or substituted with 1 or 2 substituents selected from the group consisting of F, Cl, Br, I, CF ₃ , OCF ₃ , OH, alkyl having 1, 2 or 3 carbon atoms, or alkoxy having 1 or 2 carbon atoms; particular preference is given to compounds of formula Ic in which R (1) is COR (11), where R (11) is C _x H _2x -R (14), where x is 2, and R (14) is phenyl, where phenyl is substituted with one substituent selected from the group consisting of alkoxy having 1 or 2 carbon atoms, for example methoxy.

In a further embodiment, preference is given to compounds of the formula Ic in which R (2) is hydrogen.

In a further embodiment of the invention, preference is given to compounds of the formula Ic in which R (3) is C _y H _2y -R (16), wherein y is 0, 1, 2, 3 or 4; and R (16) is alkyl having 1, 2 or 3 carbon atoms, cycloalkyl having 5 or 6 carbon atoms, phenyl or pyridyl, where each phenyl and pyridyl are unsubstituted or substituted with 1, 2 substituents selected from the group consisting of F, Cl, CF ₃ , OCF ₃ , alkyl having 1, 2 or 3 carbon atoms or alkoxy having 1 or 2 carbon atoms; particular preference is given to compounds of formula Ic in which R (3) is C _y H _2y —R (16), where y is 4, and R (16) is alkyl having 1, 2 or 3 carbon atoms, for example methyl.

In a further embodiment of the invention, preference is given to compounds of the formula Ic in which R (4) is hydrogen.

In a further embodiment of the invention, preference is given to compounds of the formula Ic in which each of R (30) and R (31) is hydrogen.

In one embodiment of the invention, preference is given to compounds of the formula Id in which one of the groups A1, A4 and A7 is a nitrogen atom, and, in each case, the other of the groups A1, A4 and A7 and each independently A2, A3, A5, A6 and A8 are CH or CR (5), where at least five of these groups are CH; particular preference is given to compounds of the formula Id in which one of A1, A4 and A7 is a nitrogen atom, and in each case the other of A1, A4 and A7 and each A2, A3, A5, A6 and A8 are CH.

In a further embodiment, preference is given to compounds of the formula Id in which R (1) is C (O) OR (9) or COR (11), where R (9) and R (11) are each independently C _x H _2x -R (14), where x is 0, 1, 2 or 3, and R (14) is cycloalkyl having 5 or 6 carbon atoms, or phenyl, where phenyl is unsubstituted or substituted with 1 or 2 substituents selected from a group consisting of F, Cl, Br, I, CF ₃ , OCF ₃ , OH, alkyl having 1, 2 or 3 carbon atoms, or alkoxy having 1 or 2 carbon atoms; particular preference is given to compounds of formula Id in which R (1) is C (O) OR (9) or COR (11), where R (9) and R (11) are each independently C _x H _2x -R ( 14), where x is 1, 2 or 3, and R (14) is phenyl.

In a further embodiment, preference is given to compounds of the formula Id in which R (2) is hydrogen.

In a further embodiment, preference is given to compounds of the formula Id in which R (3) is C _y H _2y -R (16), where y is 0, 1, 2, 3 or 4, and R (16) is alkyl, having 1, 2 or 3 carbon atoms, cycloalkyl having 3, 4, 5 or 6 carbon atoms, phenyl or pyridyl, where each phenyl and pyridyl is unsubstituted or substituted by 1 or 2 substituents selected from the group consisting of F, Cl, CF ₃ , alkyl having 1, 2 or 3 carbon atoms, and alkoxy having 1 or 2 carbon atoms; particular preference is given to compounds of the formula Id in which R (3) is C _y H _2y -R (16), where y is 1, 2 or 4, and R (16) is alkyl having 1, 2 or 3 carbon atoms for example, methyl, cycloalkyl having 3 carbon atoms, phenyl or pyridyl; where each phenyl and pyridyl is unsubstituted or substituted by two substituents selected from the group consisting of F or Cl, for example, F.

In a further embodiment, preference is given to compounds of the formula Id in which R (4) is hydrogen.

In a further embodiment of the invention, preference is given to compounds of the formula Id in which each R (30) and R (31) is hydrogen.

In a further embodiment of the invention, preference is given to compounds of the formula Ie in which X is an oxygen atom or a sulfur atom, for example, a sulfur atom.

In a further embodiment, preference is given to compounds of formula Ie in which R (1) is C (O) OR (9) or COR (11); where R (9) and R (11), each independently, is C _x H _2x -R (14), where x is 0, 1, 2, 3 or 4, and R (14) is alkyl having 1, 2 or 3 carbon atoms, cycloalkyl having 5 or 6 carbon atoms, or phenyl, where phenyl is unsubstituted or substituted by 1 or 2 substituents selected from the group consisting of F, Cl, Br, I, CF ₃ , OCF ₃ , OH, alkyl having 1, 2 or 3 carbon atoms, or alkoxy having 1 or 2 carbon atoms; particular preference is given to compounds of formula Ie in which R (1) is COR (11), where R (11) is C _x H _2x -R (14), where x is 1, and R (14) is phenyl, where phenyl is substituted with one substituent selected from the group consisting of alkoxy having 1 or 2 carbon atoms, for example methoxy.

In a further embodiment, preference is given to compounds of the formula Ie in which R (2) is hydrogen.

In a further embodiment of the invention, preference is given to compounds of the formula Ie in which R (3) is C _y H _2y -R (16), where y is 0, 1 or 2; and R (16) is alkyl having 1, 2 or 3 carbon atoms, cycloalkyl having 5 or 6 carbon atoms, phenyl or pyridyl, where each phenyl and pyridyl is unsubstituted or substituted with 1, 2 or 3 substituents selected from the group consisting of F, Cl, CF ₃ , alkyl having 1, 2 or 3 carbon atoms, or alkoxy having 1 or 2 carbon atoms; particular preference is given to compounds of formula Ie in which R (3) is C _y H _2y -R (16), where y is 1, and R (16) is phenyl, where phenyl is substituted with 2 substituents selected from the group consisting of F and Cl, e.g. F.

In a further embodiment of the invention, preference is given to compounds of the formula Ie in which R (4) is hydrogen.

In a further embodiment of the invention, preference is given to compounds of the formula Ie in which each R (5), R (6) and R (7) is hydrogen.

In a further embodiment, preference is given to compounds of the formula Ie in which each R (30) and R (31) is hydrogen.

In a further embodiment, preference is given to compounds of the formula If, in which X is an oxygen atom or a sulfur atom.

In a further embodiment, preference is given to compounds of the formula If, in which R (1) is C (O) OR (9) or COR (11), where R (9) and R (11) are each independently C _x H _2x- R (14); where x is 0, 1, 2, 3 or 4, and R (14) is alkyl having 1, 2 or 3 carbon atoms, cycloalkyl having 5 or 6 carbon atoms, or phenyl; where phenyl is unsubstituted or substituted by 1 or 2 substituents selected from the group consisting of F, Cl, Br, I, CF ₃ , OCF ₃ , OH, alkyl having 1, 2 or 3 carbon atoms, or alkoxy having 1 or 2 carbon atoms; particular preference is given to compounds of the formula If, in which R (1) is COR (11), where R (11) is C _x H _2x -R (14), where x is 1, and R (14) is phenyl, where phenyl is substituted with one substituent selected from the group consisting of alkoxy having 1 or a carbon atom, for example methoxy.

In a further embodiment, preference is given to compounds of the formula If in which R (2) is hydrogen.

In a further embodiment, preference is given to compounds of the formula If, in which R (3) is C _y H _2y —R (16), where y is 0, 1, 2, 3 or 4; and R (16) is alkyl having 1, 2 or 3 carbon atoms, cycloalkyl having 5 or 6 carbon atoms, phenyl or pyridyl, where each phenyl and pyridyl is unsubstituted or substituted with 1, 2 or 3 substituents selected from the group consisting of F, Cl, CF ₃ , alkyl having 1, 2 or 3 carbon atoms, or alkoxy having 1 or 2 carbon atoms; particular preference is given to compounds of the formula If, in which R (3) is C _y H _2y —R (16); where y is 1 or 4, and R (16) is alkyl having 1, 2 or 3 carbon atoms, for example methyl or phenyl, where phenyl is substituted with two substituents selected from the group consisting of F and Cl, for example, F.

In a further embodiment, preference is given to compounds of the formula If in which R (4) is hydrogen.

In a further embodiment, preference is given to compounds of the formula If, in which each R (5), R (6) and R (7) are hydrogen.

In a further embodiment, preference is given to compounds of the formula If, in which each R (30) and R (31) is hydrogen.

,In a further embodiment, preference is given to compounds of the formula Ih in which R (1) is

,

,where A is —C _n H _2n -, where n is 0, 1 or 2, D is a bond or an oxygen atom, E is —C _m H _2m -, where m is 0 or 1, R (8) is a hydrogen atom or an alkyl having 1, 2, 3 or 4 carbon atoms, R (9) is a hydrogen atom or an alkyl having 1, 2, 3 or 4 carbon atoms, R (12) is an alkyl having 1, 2, 3 or 4 carbon atoms, or cyclopropyl, and R (11) is phenyl or pyridyl, where each phenyl and pyridyl is unsubstituted or substituted with 1, 2 or 3 substituents selected from the group consisting of F, Cl, CF ₃ , OCF ₃ , CN, C OMe, OH, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino; particular preference is given to compounds of formula Ih in which R (1) is

,

where A is —C _n H _2n -, where n is 0; D is a bond, E is —C _m H _2m -, where m is 0; each R (8) and R (9) is a hydrogen atom, R (12) is alkyl having 1, 2 or 3 carbon atoms, for example ethyl, and R (11) is phenyl or pyridyl, where each phenyl and pyridyl is unsubstituted or substituted with one substituent selected from the group consisting of alkoxy having 1 or 2 carbon atoms, for example methoxy.

In a further embodiment of the invention, preference is given to compounds of formula Ih in which R (2) is hydrogen.

In a further embodiment of the invention, preference is given to compounds of formula Ih in which R (3) is alkyl having 3, 4 or 5 carbon atoms, or phenyl, where phenyl is unsubstituted or substituted with 1, 2 or 3 substituents selected from the group consisting of from F, Cl, CF ₃ , OCF ₃ , COOMe, CONH ₂ , COMe, OH, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino; particular preference is given to compounds of formula Ih in which R (3) is alkyl having 3, 4 or 5 carbon atoms, for example 4 carbon atoms, or phenyl, where phenyl is substituted with one substituent selected from the group consisting of alkoxy having 1 or 2 carbon atoms, for example methoxy.

In a further embodiment of the invention, preference is given to compounds of the formula Ih in which R (5) is a hydrogen or methoxy atom, and each R (4), R (6) and R (7) is a hydrogen atom.

,In a further embodiment, preference is given to compounds of formula Ij in which R (1) is

,

,where A is —C _n H _2n -, where n is 0 or 1, D is a bond or —O—, E is —C _m H _2m -, where m is 0 or 1, R (8) is an atom hydrogen or alkyl having 1, 2 or 3 carbon atoms, R (9) is a hydrogen atom, ethyl or methyl, R (11) is phenyl, naphthyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolyl, indazolyl, quinolyl, isoquinolyl, phthalazinyl, quinoxalinyl, quinazolinyl or cinnolinyl, where each phenyl, naphthyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolyl, indazolyl, x nolil, isoquinolyl, phthalazinyl, quinoxalinyl, quinazolinyl or cinnolinyl is unsubstituted or substituted by 1 or 2 substituents selected from the group consisting of F, Cl, CF _3, OCF _3, CN, COMe, methoxy, ethoxy, dimethylamino, sulfamoyl and methylsulfonyl, and R (12) is alkyl having 1, 2 or 3 carbon atoms, ethynyl, cyclopropyl, phenyl, naphthyl or heteroaryl, where each phenyl, naphthyl and heteroaryl is unsubstituted or substituted with 1 or 2 substituents selected from the group consisting of F , Cl, CF _3, OCF _3, CN, COMe, ethoxy, dimethylamino, sulfamyl la, methylsulfonyl and methylsulfonylamino; particular preference is given to compounds of formula Ih in which R (1) is

,

where A is —C _n H _2n -, where n is 0, D is a bond, E is —C _m H _2m -, where m is 0, R (8) is a hydrogen atom, R (9) is a hydrogen atom, R (11) is unsubstituted phenyl and R (12) is alkyl having 1, 2 or 3 carbon atoms, for example ethyl.

In a further embodiment of the invention, preference is given to compounds of the formula Ij in which R (2) is a hydrogen atom.

In a further embodiment of the invention, preference is given to compounds of formula Ij in which R (3) is heteroaryl, where heteroaryl is unsubstituted or substituted with 1 or 2 substituents selected from the group consisting of F, Cl, CF ₃ , OCF ₃ , CN, COMe , methyl, methoxy, ethoxy, dimethylamino, sulfamoyl and methylsulfonyl; particular preference is given to compounds of the formula Ih in which R (3) is furanyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, thiazolyl, isoxiazolyl, pyridinyl, pyriminyl, pyriminyl, pyriminyl, pyriminyl, pyriminyl, pyriminyl, pyriminyl isoquinolyl, phthalazinyl, quinoxalinyl, quinazolinyl, cinnolinyl, for example, quinolyl.

In a further embodiment, preference is given to compounds of formula Ij in which R (5) is a hydrogen atom or F, for example F, and each R (4), R (6) and R (7) is a hydrogen atom. R (1) in the compounds of formulas Ih and Ij is connected via the nitrogen atom of the residue R (1) to the carbonyl residue of the compounds of formulas Ih and Ij.

Especially preferred is the use of compounds selected from the group which comprises

2- (butyl-1-sulfonylamino) -N- [1 (R) - (6-methoxypyridin-3-yl) propyl] benzamide,

2- (butyl-1-sulfonylamino) -N- [1 (S) - (6-methoxypyridin-3-yl) propyl] benzamide,

N- (2-pyridin-3-yl-ethyl) -2 '- {[2- (4-methoxyphenyl) acetylamino] methyl} biphenyl-2-carboxamide,

(S) -5-fluoro-2- (quinoline-8-sulfonylamino-N- (1-phenylpropyl) benzamide,

(S) -5-methoxy-2- (4-methoxybenzenesulfonylamino) -N- (1-phenylpropyl) benzamide,

N- (2- (R) -hydroxypropyl) -2 '- (α- (S) -methylbenzyloxycarbonylaminomethyl) biphenyl-2-carboxamide,

N- (2,4-difluorobenzyl) -5-chloro-2 '- {[2- (4-methoxyphenyl) acetylamino] methyl} biphenyl-2-carboxamide,

benzyl {2 '- [methyl (2-pyridin-2-yl-ethyl) carbamoyl] biphenyl-2-yl-methyl} carbamate,

N- (2,4-difluorobenzyl) -3- (2 - {[2- (4-methoxyphenyl) acetylamino] methyl} phenyl) thiophene-2-carboxamide,

N- (2,4-difluorobenzyl) -5- (2 - {[2- (4-methoxyphenyl) acetylamino] methyl} phenyl) furan-2-carboxamide,

N- (3-methylbutyl) -2- (2 - {[2- (4-methoxyphenyl) acetylamino] methyl} phenyl) furan-3-carboxamide,

N- (2,4-difluorobenzyl) -2- (2 - {[2- (4-methoxyphenyl) acetylamino] methyl} phenyl) thiophene-3-carboxamide,

(S) -1-phenylethyl {2- [2- (2-pyridin-2-yl-ethylcarbamoyl) pyridin-3-yl] benzyl} carbamate,

N-Cyclopropylmethyl-3- {2 - [((R) -3-phenylbutyrylamino) methyl] phenyl} pyridine-2-carboxamide,

benzyl {2- [3- (2,4-difluorobenzylcarbamoyl) pyridin-2-yl] benzyl} carbamate,

benzyl {4- [3- (3-methylbutylcarbamoyl) phenyl] pyridin-3-ylmethyl} carbamate,

N- (3-methylbutyl) -2 '- {[3- (4-methoxyphenyl) propionylamino] methyl} -6-methylbiphenyl-3-carboxamide

and N-indan-1-yl-2-methyl-5- (3-methylbutylsulfamoyl) benzamide, and / or their physiologically compatible salts.

If in the compounds of formulas I, Ia, Ib, Ic, Id, Ie, If, Ig, Ih and Ij any groups, substituents, members of the cycle, numbers or other characteristics, such as, for example, R14, alkyl groups and so on, are found several times, then all of them, independently of each other, can have any of the indicated values; and in each case can be identical or different from each other.

Alkyl radicals and alkylene radicals may be branched or unbranched. This also applies to alkylene radicals of the formulas C _r H _2r , C _x H _2x , C _s H _2s , C _y H _2y , C _Z H _2z , C _v H _2v , C _w H _2w , C _n H _2n , C _m H _2m , C _p H _2p and (CH ₂ ) _X. Alkyl radicals and alkylene radicals may also have a straight or branched chain when they are substituted or are present in other radicals, for example, fluoroalkyl radicals or alkoxy radicals. Examples of alkyl radicals are methyl, ethyl, n-propyl, isopropyl (= 1-methylethyl), n-butyl, isobutyl (= 2-methylpropyl), sec-butyl (= 1-methylpropyl), tert-butyl (= 1,1 dimethylethyl), n-pentyl, isopentyl, tert-pentyl, neopentyl, hexyl and heptyl. Divalent radicals derived from these radicals, for example, methylene, 1,1-ethylene, 1,2-ethylene, 1,1-propylene, 1,2-propylene, and so on, are examples of alkylene radicals. Preferred alkyl radicals are methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl and tert-butyl. In alkyl radicals, one or more hydrogen atoms, for example 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15, may be substituted with fluorine atoms. Examples of such fluoroalkyl radicals are trifluoromethyl, 2,2,2-trifluoroethyl and pentafluoroethyl. Substituted alkyl radicals may be substituted at any position.

Alkynyl radicals may be straight or branched chain. This is also true for the case when they have substituents, for example, for fluoroalkynyl radicals. Alkynyl radicals may contain unsaturation in various positions, as well as be polyunsaturated. Examples of alkynyl radicals are ethynyl, n-prop-1-ynyl, n-prop-2-ynyl, n-but-1-ynyl, n-but-2-ynyl, n-but-3-ynyl, n-butyl 1,3-diinyl and sec-but-2-ynyl (= 1-methylprop-2-ynyl). In alkynyl radicals, one or more hydrogen atoms, for example 1, 2, 3, 4, 5, 6, or 7 atoms, may be substituted with fluorine atoms. Substituted alkynyl radicals may be substituted in any positions.

Examples of cycloalkyl radicals are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecanyl and cycloundecanyl. In cycloalkyl radicals, one or more hydrogen atoms, for example 1, 2, 3, 4, 5, 6, 7, or 8 atoms, can be replaced by fluorine atoms. Substituted cycloalkyl radicals may be substituted in any positions.

Aryl is, for example, phenyl and 2- or 3-naphthyl.

Phenyl radicals can be unsubstituted or mono- or polysubstituted, for example, mono-, di- or trisubstituted, when substituted by identical or different radicals. When the phenyl radical is substituted, it preferably has one or two identical or different substituents. This applies equally to substituted phenyl radicals, for example in groups such as phenylalkyl groups or phenyloxy groups. In monosubstituted phenyl radicals, the substituent may be in position 2, position 3, or position 4. Disubstituted phenyl may be substituted in 2,3-positions, 2,4-positions, 2,5-positions, 2,6-positions, 3,4-positions or 3.5 positions. In trisubstituted phenyl radicals, the substituents can be in 2,3,4-positions, 2,3,5-positions, 2,4,5-positions, 2,4,6-positions, 2,3,6-positions or 3, 4,5 positions.

Heteroaryl radicals are compounds containing aromatic rings in which one or more ring atoms are oxygen atoms, sulfur atoms or nitrogen atoms, for example, contain 1, 2 or 3 nitrogen atoms, 1 or 2 oxygen atoms, 1 or 2 sulfur atoms, or a combination of various heteroatoms. Heteroaryl radicals can be attached at all positions, for example, at 1-position, 2-position, 3-position, 4-position, 5-position, 6-position, 7-position or 8-position. Heteroaryl radicals may be unsubstituted or mono- or polysubstituted, for example, be mono-, di- or trisubstituted with identical or different radicals. This applies equally to heteroaryl radicals, such as, for example, heteroarylalkyl radicals. Examples of heteroaryl radicals are furanyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolinolinolinolinolinolinolinolinolinolinolinolinolinolinolinolinolinolinolinolinolinolinolinolinolinolinolinolinolinolinolinolinolinolinolinolinolinolinolinolinolinolinolinolinolinolinolinolinolinolinolinolinolinolinolinolinolinolinolinolinolinolinolinolinolinolinolinolinolinolinolinolinolinolinolinolinolinolinolinolinolinolinolinolinolinolinolinolinolinol Heteroaryl radicals, in particular, are 2- or 3-thienyl, 2- or 3-furyl, 1-, 2- or 3-pyrrolyl, 1-, 2-, 4- or 5-imidazolyl, 1-, 3-, 4- or 5-pyrazolyl, 1,2,3-triazol-1 -, - 4- or -5-yl, 1,2,4-triazol-1-, -3- or -5-yl, 1- or 5-tetrazolyl, 2-, 4- or 5-oxazolyl, 3-, 4- or 5-isoxazolyl, 1,2,3-oxadiazol-4- or -5-yl, 1,2,4-oxadiazol-3- or -5-yl, 1,3,5-oxadiazol-2-yl or -5-yl, 2-, 4- or 5-thiazolyl, 3-, 4- or 5-isothiazolyl, 1,3,4-thiadiazole -2- or -5-yl, 1,2,4-thiadiazol-3- or -5-yl, 1,2,3-thiadiazol-4- or -5-yl, 2-, 3- or 4-pyridyl , 2-, 4-, 5- or 6-pyrimidinyl, 3- or 4-pyridazinyl, pyrazinyl, 1-, 2-, 3-, 4-, 5-, 6- or 7-indolyl, 1-, 2- 4- and and 5-benzimidazolyl, 1-, 3-, 4-, 5-, 6- or 7-indazolyl, 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolyl, 1-, 3 -, 4-, 5-, 6-, 7- or 8-isoquinolyl, 2-, 4-, 5-, 6-, 7- or 8-quinazolinyl, 3-, 4-, 5-, 6-, 7 - or 8-cinnolinyl, 2-, 3-, 5-, 6-, 7- or 8-quinoxalinyl, 1-, 4-, 5-, 6-, 7- or 8-phthalazinyl. The corresponding N-oxides of these compounds are also included, i.e., for example, 1-hydroxy-2-, -3- or -4-pyridyl.

Particular preference is given to aromatic heterocycles such as 2- or 3-thienyl, 2- or 3-furyl, 1-, 2- or 3-pyrrolyl, 1-, 2-, 4- or 5-imidazolyl, 2-, 3- 4-, 5-, 6-, 7- or 8-quinolyl, 1-, 3-, 4- or 5-pyrazolyl, 2-, 3- or 4-pyridyl, 2- or 3-pyrazinyl, 2-, 4-, 5- or 6-pyrimidinyl; and 3- or 4-pyridazinyl.

N-containing heterocycles are cyclic compounds in which one or more ring atoms are nitrogen atoms, for example, 1, 2 or 3 nitrogen atoms. N-containing heterocycles can be attached at all positions, for example, at position 1, position 2, position 3, position 4, position 5, position 6, position 7 or position 8. N-containing heterocycles can be unsubstituted or mono- or polysubstituted, for example, can be mono-, di- or trisubstituted by identical or different radicals. N-containing heterocycles having 1, 2, 3, 4, 5, 6, 7, 8 or 9 carbon atoms represent, in particular, the following aromatic systems: 1-, 2- or 3-pyrrolyl, 1-, 2 -, 4- or 5-imidazolyl, 1-, 3-, 4- or 5-pyrazolyl, 1,2,3-triazol-1-, -4- or -5-yl, 1,2,4-triazol- 1-, -3- or -5-yl, 1- or 5-tetrazolyl, 2-, 4- or 5-oxazolyl, 3-, 4- or 5-isoxazolyl, 1,2,3-oxadiazole-4- or -5-yl, 1,2,4-oxadiazol-3- or -5-yl, 1,3,4-oxadiazol-2-yl or -5-yl, 2-, 4- or 5-thiazolyl, 3- 4- or 5-isothiazolyl, 1,3,4-thiadiazol-2- or -5-yl, 1,2,4-thiadiazol-3- or -5-yl, 1,2,3-thiadiazol-4- or -5-yl, 2-, 3- or -4-pyridyl, 2-, 4-, 5- or 6-pyrimidinyl, 3- or 4- pyridazinyl, pyrazinyl, 1-, 2-, 3-, 4-, 5-, 6- or 7-indolyl, 1-, 2-, 4- or 5-benzimidazolyl, 1-, 3-, 4-, 5- 6- or 7-indazolyl, 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolyl, 1-, 3-, 4-, 5-, 6-, 7- or 8- isoquinolyl, 2-, 4-, 5-, 6-, 7- or 8-quinazolinyl, 3-, 4-, 5-, 6-, 7- or 8-cinnolinyl, 2-, 3-, 5-, 6 -, 7- or 8-quinoxalinyl, 1-, 4-, 5-, 6-, 7- or 8-phthalazinyl.

Particular preference is given to N-containing heterocycles such as pyrrolyl, imidazolyl, quinolyl, pyrazolyl, pyridyl, pyrazinyl, pyrimidinyl and pyridazinyl.

N-containing aromatic heterocycles are aromatic cyclic compounds in which one or more ring atoms are nitrogen atoms, for example, 1, 2 or 3 nitrogen atoms. N-containing aromatic heterocycles can be attached at all positions, for example, at position 1, position 2, position 3, position 4, position 5, position 6, position 7 or position 8. N-containing aromatic heterocycles can be unsubstituted or mono- or polysubstituted, for example, they can be mono-, di- or trisubstituted by identical or different radicals. N-containing aromatic heterocycles having 1, 2, 3, 4, 5, 6, 7, 8 or 9 carbon atoms, in particular, are aromatic systems such as 1-, 2- or 3-pyrrolyl, 1-, 2-, 4- or 5-imidazolyl, 1-, 3-, 4- or 5-pyrazolyl, 1,2,3-triazol-1-, -4- or -5-yl, 1,2,4-triazole -1-, -3- or -5-yl, 1- or 5-tetrazolyl, 2-, 4- or 5-oxazolyl, 3-, 4- or 5-isoxazolyl, 1,2,3-oxadiazole-4- or -5-yl, 1,2,4-oxadiazol-3- or -5-yl, 1,3,4-oxadiazol-2-yl or -5-yl, 2-, 4- or 5-thiazolyl, 3 -, 4- or 5-isothiazolyl, 1,3,4-thiadiazol-2- or -5-yl, 1,2,4-thiadiazol-3- or -5-yl, 1,2,3-thiadiazol-4 - or -5-yl, 2-, 3- or -4-pyridyl, 2-, 4-, 5- or 6-pyrim dinyl, 3- or 4-pyridazinyl, pyrazinyl, 1-, 2-, 3-, 4-, 5-, 6- or 7-indolyl, 1-, 2-, 4- or 5-benzimidazolyl, 1-, 3 -, 4-, 5-, 6- or 7-indazolyl, 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolyl, 1-, 3-, 4-, 5-, 6 -, 7- or 8-isoquinolyl, 2-, 4-, 5-, 6-, 7- or 8-quinazolinyl, 3-, 4-, 5-, 6, 7- or 8-cinnolinyl, 2-, 3 -, 5-, 6-, 7- or 8-quinoxalinyl, 1-, 4-, 5-, 6-, 7- or 8-phthalazinyl. The corresponding N-oxides of these compounds are also included, that is, for example, 1-hydroxy-2-, -3- or -4-pyridyl.

Particular preference is given to N-containing heterocycles such as pyrrolyl, imidazolyl, quinolyl, pyrazolyl, pyridyl, pyrazinyl, pyrimidinyl and pyridazinyl.

Pyridyl is 2-, 3- or 4-pyridyl. Thienyl are 2- or 3-thienyl. Furyl are 2- or 3-furyl.

In the case when there is a di - or polysubstitution of the radical, the substituents may be identical or different.

When the compounds of formula Ia, Ib, Ic, Id, Ie, If, Ig, Ih or Ij contain one or more acid or basic groups or one or more basic heterocycles, the corresponding physiologically or toxylologically compatible salts are also included in the invention, in particular pharmaceutically applicable salts. For example, compounds of formulas Ia, Ib, Ic, Id, Ie, If, Ig, Ih or Ij can be deprotonated at the sulfonamide group and used, for example, in the form of alkali metal salts, preferably sodium or potassium salts, or in the form of ammonium salts for example, in the form of salts formed with ammonia or organic amines or amino acids. Compounds of formulas Ia or Ib that contain a pyridine or quinoline substituent can also be used in the form of their physiologically compatible acid addition salts with inorganic or organic acids, for example, in the form of hydrochlorides, phosphates, sulfates, methanesulfonates, acetates, lactates, maleates, fumarates , malates, gluconates, and so on. Compounds of formula Ia or Ib may also be in the form of trifluoroacetates.

Compounds of formulas Ia, Ib, Ic, Id, Ie, If, Ig, Ih or Ij, if substituted, may be present in stereoisomeric forms. When the compounds of formulas Ia, Ib, Ic, Id, Ie, If, Ig, Ih or Ij contain one or more centers of asymmetry, they may each independently have an S configuration or R configuration. The invention includes all possible stereoisomers, for example, enantiomers or diastereomers, and mixtures of two or more stereoisomeric forms, for example, enantiomers and / or diastereomers, in any ratio. Thus, enantiomers, for example, are included in enantiomerically pure forms in the form of both levorotatory and dextrorotatory antipodes, as well as mixtures of two enantiomers in various ratios or as racemates. If desired, the preparation of individual stereoisomers can be carried out by separating the mixture by conventional methods, or, for example, using modules containing isomerically pure substances for the synthesis.

The present invention encompasses all tautomeric forms of the compounds of formulas Ia, Ib, Ic, Id, Ie, If, Ig, Ih or Ij.

Compounds of formulas Ia, Ib, Ic, Id, Ie, If, Ig, Ih or Ij can be prepared according to the preparation methods described in WO 01/00573, WO 01/025189, WO 02/044137, WO 02/046162, WO 02/048131, WO 02/087568, WO 02/088073, WO 02/100825.

The compounds of formulas Ia, Ib, Ic, Id, Ie, If, Ig, Ih or Ij according to the invention can be used as such, in a mixture with each other or in the form of pharmaceutical preparations for the treatment or prevention of respiratory disorders, respiratory sleep disorders, seizures central and obstructive sleep apnea, upper respiratory tract obstruction syndrome, Cheyne-Stokes breathing, snoring, central respiratory dysregulation, sudden infant death, postoperative hypoxia and apnea, muscle respiratory disorders, respiratory disorders after prolonged ventilation, respiratory disorders during adaptation in the high mountains, acute and chronic pulmonary disorders with hypoxia and hypercapnia, neurodegenerative disorders, dementia, Alzheimer's disease, Parkinson's disease, Huntington's disease; cancer, breast cancer, lung cancer, colon cancer, and prostate cancer in humans or animals.

Pharmaceutical preparations contain as an active ingredient an effective dose of at least one compound of the formula Ia, Ib, Ic, Id, Ie, If, Ig, Ih and / or Ij and / or its physiologically compatible salt, in addition to conventional carriers and excipients, pharmaceutically non-objectionable, and also optionally one or more other active pharmacological ingredients. Pharmaceutical preparations usually contain from 0.1 to 90 wt.% Compounds of formulas Ia-Ij and / or their physiologically compatible salts.

Pharmaceutical preparations can be obtained, in fact, in a known manner. To this end, the active ingredients and / or their physiologically compatible salts, together with one or more solid or liquid pharmaceutical carriers and / or excipients, are converted into a suitable form or dosage form, which can then be used as a medicine in human medicine or veterinary medicine.

Medicines that contain the inventive compounds of formulas Ia-Ij and / or their pharmaceutically compatible salts can be administered, for example, orally, parenterally, intravenously, rectally, nasally, inhalation, or topically, in particular oral, intravenous or nasal administration are preferred, depending on the particular case of the disease, the route of administration.

Excipients that are suitable for the desired pharmaceutical preparation are well known to those skilled in the art. In addition to solvents, gelling agents, suppository bases, tablet excipients and other carriers of active ingredients, for example, antioxidants, dispersants, emulsifiers, antifoams, flavorings, preservatives, solubilizers, depot effect agents, buffers or colorants can be used.

For oral administration forms, the active compounds are mixed with additives suitable for this purpose, such as carriers, stabilizers or inert diluents, and by conventional methods, they are converted into suitable dosage forms, such as tablets, coated tablets, hard gelatine capsules, aqueous, alcoholic or oil solutions. Examples of useful inert carriers include gum arabic, magnesia, magnesium carbonate, potassium phosphate, lactose, glucose or starch, in particular corn starch. The preparation may be either in the form of dry granules or in the form of wet granules. Examples of suitable oily carriers or applicable solvents are vegetable or animal oils, such as sunflower oil or fish oil. Suitable solvents for aqueous or alcoholic solutions include, for example, water, ethanol or sugar solutions, or mixtures thereof. Additional excipients also used for other forms of administration are, for example, polyethylene glycols and polypropylene glycols.

For subcutaneous, intramuscular or intravenous routes of administration, the active compounds used, if necessary, together with substances customary for such a purpose, such as solubilizers, emulsifiers or other excipients, are converted into a solution, suspension or emulsion. Examples of suitable solvents are water, physiological saline or alcohols, for example ethanol, propanol, glycerin, and also, in addition, solutions of sugars, such as glucose or mannitol solutions, or mixtures of various of these solvents.

Examples of suitable pharmaceutical preparations for administration in the form of aerosols or sprays are, for example, for nasal administration, solutions, suspensions, emulsions or vesicular or micellar dosage forms of the active ingredients or their physiologically compatible salts in water or in a pharmaceutically acceptable water-soluble or oily solvent, or in a mixture such solvents. Also suitable for administration in the form of aerosols or sprays, for example for nasal administration, are the powders of the active ingredients or their physiologically compatible salts. If necessary, all preparations may also contain other pharmaceutical excipients, such as isotonic additives, surfactants, emulsifiers and stabilizers, as well as propellant gas. Additionally, these preparations may be in the form of lyophilized products. Typically, the preparations contain the active ingredient in a concentration of from about 0.001 to 10 wt.%, In particular from about 0.05 to 5 wt.%.

The dosage of the active compounds or their physiologically compatible salts, which according to the invention should be administered to the patient, depends on the particular type of disease, and usually for optimal effects it should be adjusted in accordance with the circumstances of specific cases of the disease. For example, the dosage certainly depends on the frequency of administration and on the strength and duration of action of the compounds used in each case for treatment or prophylaxis, but also on the nature and severity of the disease being treated, as well as on gender, age, body weight and individual susceptibility the person or animal being treated; and whether emergency treatment in an acute situation or treatment of a chronic disease, or prevention.

The dosage of the compounds of formulas Ia, Ib, Ic, Id, Ie, If, Ig, Ih and / or Ij can usually vary within the range of 1 mg to 1 g per day per person (with a body weight of approximately 75 kg), preferably 5 to 750 mg per day per person. However, higher doses may also be adequate. The daily dose of the active ingredient can be immediately entered completely, or it can be divided between a number of doses, for example, 2, 3 or 4.

EXPERIMENTAL PART

LIST OF ABBREVIATIONS

EDAC N-ethyl-N '- (3-dimethylaminopropyl) carbodiimide hydrochloride

EMG electromyographic

DMSO dimethyl sulfoxide

HOBT 1-hydroxy-1-H-benzotriazole

n.s. inconsequential

PEG polyethylene glycol

THF tetrahydrofuran

SEM standard error

vs. in comparison with

Example 1:

2- (Butyl-1-sulfonylamino) -N- [1 (R) - (6-methoxypyridin-3-yl) propyl] benzamide and 2- (butyl-1-sulfonylamino) -N- [1 (S) - ( 6-methoxypyridin-3-yl) propyl] benzamide

a) 2- (Butyl-1-sulfonylamino) benzoic acid

20 g (188 mmol) of sodium carbonate was added to a suspension of 20 g (146 mmol) of 2-aminobenzoic acid in 250 ml of water. Then, 11.4 g (72.8 mmol) of butyl sulfonyl chloride was added dropwise, and the reaction mixture was stirred for 2 days at room temperature. The mixture was acidified with concentrated hydrochloric acid and stirred for 3 hours at room temperature, and the precipitated product was filtered off with suction turned on. Drying under reduced pressure afforded 9.6 g of 2- (butyl-1-sulfonylamino) benzoic acid.

b) 1- (6-Methoxypyridin-3-yl) propylamine

3 ml (23.2 mmol) of 5-bromo-2-methoxypyridine was added at -70 ° C to a solution of 10.2 ml of butyllithium (2.5 M solution in hexane; 25.5 mmol) in 50 ml of diethyl ether. After 10 minutes, 1.4 ml (19.5 mmol) of propionitrile were added. After 2 hours at -70 ° C, the reaction mixture was allowed to slowly warm to room temperature. Then 2.2 g of sodium sulfate decahydrate was added and the mixture was allowed to stir for 1 hour. After the subsequent addition of 5 g of magnesium sulfate and brief stirring, the salts were filtered off and the filtrate was concentrated. The residue was dissolved in 70 ml of methanol and 1.1 g (28 mmol) of sodium borohydride was added at 0 ° C. After stirring overnight, the reaction mixture was adjusted to pH 2 using concentrated hydrochloric acid and concentrated on a rotary evaporator. The residue was mixed with 10 ml of water and was extracted once with diethyl ether. Then the aqueous phase was extracted with sodium bicarbonate and concentrated under reduced pressure. The residue was extracted with ethyl acetate. Drying and concentration of ethyl acetate extracts afforded 1.4 g of racemic 1- (6-methoxypyridin-3-yl) propylamine.

c) 2- (Butyl-2-sulfonylamino) -N- [1 (R) - (6-methoxypyridin-3-yl) propyl] benzamide

To a solution of 8.0 g (31.1 mmol) of 2- (butyl-1-sulfonylamino) benzoic acid in 250 ml of tetrahydrofuran was added 4.4 g (32.7 mmol) of 1-hydroxy-1H-benzotriazole and 6.3 g (32.7 mmol) of N-ethyl-N '- (3-dimethylaminopropyl) carbodiimide hydrochloride and the reaction mixture was stirred for 90 minutes. Then, a solution of 5.4 g (32.7 mmol) of racemic 1- (6-methoxypyridin-3-yl) propylamine in 20 ml of tetrahydrofuran was added dropwise and the mixture was stirred overnight. The reaction mixture was mixed with 250 ml of water and extracted with 300 ml of ethyl acetate. The organic phase was extracted 5 times, each time using 100 ml of a saturated sodium hydrogen carbonate solution, and then dried over magnesium sulfate. This gave 9.0 g of 2- (butyl-1-sulfonylamino) -N- [1- (6-methoxypyridin-3-yl) propyl] benzamide.

Enantiomers were separated by preparative HPLC (HPLC) on a Chiralpak ADH column (250 × 4.6 mm). Used: eluent: 10: 1: 1 heptane / ethanol / methanol mixture; temperature: 30 ° C; flow rate: 1 ml / min. First, 4.0 g of 2- (butyl-1-sulfonylamino) -N- [1 (R) - (6-methoxypyridin-3-yl) propyl] benzamide was eluted with a retention time of 5.9 minutes. After the mixed fraction, 3.0 g of 2- (butyl-1-sulfonylamino) -N- [1 (S) - (6-methoxypyridin-3-yl) propyl] benzamide was obtained, with a retention time of 7.2 minutes.

2 g of 2- (butyl-1-sulfonylamino) -N- [1 (R) - (6-methoxypyridin-3-yl) propyl] benzamide was dissolved in 9 ml of isopropanol with heating, then 8 ml of warm water was added and the reaction mixture was left cool slowly overnight. Filtration at 0 ° C with suction gave 1.5 g of 2- (butyl-1-sulfonylamino) -N- [1 (R) - (6-methoxypyridin-3-yl) propyl] benzamide as colorless needle crystals with a melting point 97 ° C.

Example 2:

N- (2-pyridin-3-yl-ethyl) -2 '- {[2- (4-methoxyphenyl) acetylamino] methyl} biphenyl-2-carboxamide

15.5 g (0.115 mol) of HOBT and 21.9 g (0.115 mol) of EDAC were added to a solution of 37.8 g (0.11 mol) of 2 '- (tert-butoxycarbonylaminomethyl) biphenyl-2-carboxylic acid (Brandmeier, V .; Sauer, WHB; Feigel, M .; Helv. Chim. Acta 1994, 77 (1), 70-85) in 550 ml of THF and the reaction mixture was stirred at room temperature for 45 minutes. Then, 14.0 g (0.115 mol) of 3- (2-aminoethyl) pyridine was added and the mixture was stirred at room temperature (RT) overnight. After adding 400 ml of water and 500 ml of ethyl acetate and vigorous stirring, the phases were separated. The organic phase was washed once with 400 ml of a saturated solution of sodium chloride and two times with a saturated solution of sodium bicarbonate (each time using 400 ml). After drying over magnesium sulfate in the presence of activated carbon, the mixture was filtered and concentrated on a rotary evaporator.

The resulting intermediate (40.7 g) was dissolved in 600 ml of methylene chloride, and then 100 ml of trifluoroacetic acid was slowly added dropwise. After stirring overnight, the reaction mixture was concentrated under reduced pressure. The residue was mixed with 250 ml of ethyl acetate and, to distill off the excess trifluoroacetic acid, was concentrated again. 72.8 ml (530 mmol) of triethylamine was added dropwise to the resulting crude product dissolved in 170 ml of methylene chloride, and 1 g of DMAP was added. Then, at 5-10 ° C., 18.7 g (100 mmol) of 4-methoxyphenylacetyl chloride was added dropwise over 30 minutes, and the mixture was stirred at room temperature overnight. After adding 150 ml of water and vigorous stirring, the phases were separated and the organic phase was washed once with 100 ml of sodium chloride solution, once with 25 ml of 1M hydrochloric acid, and twice (each time using 100 ml) with saturated sodium bicarbonate solution. After drying over magnesium sulfate and activated carbon, the mixture was concentrated under reduced pressure. The resulting oil was dissolved in hot acetonitrile and allowed to slowly crystallize. 21.5 g of N- (2-pyridin-3-yl-ethyl) -2 '- {[2- (4-methoxyphenyl) acetylamino] methyl} biphenyl-2-carboxamide are obtained, with a melting point of 116 ° C.

Example 3:

(S) -5-fluoro-2- (quinoline-8-sulfonylamino) -N- (1-phenylpropyl) benzamide sodium salt

a) 5-Fluoro-2- (quinoline-8-sulfonylamino) benzoic acid

A reaction mixture consisting of 10.0 g (64 mmol) of 5-fluoro-2-aminobenzoic acid, 16.3 g (193 mmol) of sodium bicarbonate and 16.3 g of 8-quinoline sulfonyl chloride in 325 ml of water and 325 ml of ethyl acetate, with room temperature was stirred overnight. Then the aqueous phase was removed and 50 ml of ethyl acetate was extracted once. Then, the aqueous phase was acidified with concentrated hydrochloric acid and stirred for 2 hours. The precipitated solid was filtered off with suction turned on and dried under reduced pressure to obtain 19.5 g of 5-fluoro-2- (quinoline-8-sulfonylamino) benzoic acid.

b) (S) -5-Fluoro-2- (quinoline-8-sulfonylamino) -N- (1-phenylpropyl) benzamide

5.5 g (15.9 mmol) of 5-fluoro-2- (quinolin-8-sulfonylamino) benzoic acid and 2.3 g (16.7 mmol) of (S) -phenylpropylamine were used to obtain 5.7 g of the above the name of the compound according to the method given in WO 02100825.

Mp: 163 ° C

c) 2 ml of a 30% sodium methylate solution was added to a solution of 5 g of (S) -5-fluoro-2- (quinolin-8-sulfonylamino) -N- (1-phenylpropyl) benzamide in 120 ml of ethyl acetate. The precipitated sodium salt was filtered off with suction and recrystallized from 25 ml of ethanol to obtain 3.3 g of the sodium salt of (S) -5-fluoro-2- (quinoline-8-sulfonylamino) -N- (1-phenylpropyl) benzamide.

Example 4:

(S) -5-Methoxy-2- (4-methoxybenzenesulfonylamino) -N- (1-phenylpropyl) benzamide

The compound was prepared according to the synthesis method described in WO 02088073.

Example 5:

N- (2- (R) -hydroxypropyl) -2 '- (α- (S) -methylbenzyloxycarbonylaminomethyl) biphenyl-2-carboxamide

The compound was prepared according to the synthesis method described in WO 0125189.

Example 6:

N- (2,4-Difluorobenzyl) -5-chloro-2 '- {[2- (4-methoxyphenyl) acetylamino] methyl} biphenyl-2-carboxamide

The compound was prepared according to the synthesis method described in WO 0125189.

Example 7

Benzyl {2 '- [methyl- (2-pyridin-2-yl-ethyl) carbamoyl] biphenyl-2-yl-methyl} carbamate

The compound was prepared according to the synthesis method described in WO 0125189.

Example 8:

N- (2,4-Difluorobenzyl) -3- (2 - {[2- (4-methoxyphenyl) acetylamino] methyl} phenyl) thiophene-2-carboxamide

The compound was prepared according to the synthesis method described in WO 0248131.

Example 9:

N- (2,4-Difluorobenzyl) -5- (2 - {[2- (4-methoxyphenyl) acetylamino] methyl} phenyl) furan-2-carboxamide

The compound was prepared according to the synthesis method described in WO 0248131.

Example 10:

N- (3-methylbutyl) -2- (2 - {[2- (4-methoxyphenyl) acetylamino] methyl} phenyl) furan-3-carboxamide

The compound was prepared according to the synthesis method described in WO 0248131.

Example 11:

N- (2,4-Difluorobenzyl) -2- (2 - {[2- (4-methoxyphenyl) acetylamino] methyl} phenyl) thiophene-3-carboxamide

The compound was prepared according to the synthesis method described in WO 0248131.

Example 12:

(S) -1-Phenylethyl {2- [2- (2-pyridin-2-yl-ethylcarbamoyl) pyridin-3-yl] benzyl} carbamate

The compound was prepared according to the synthesis method described in WO 0246162.

Example 13:

N-Cyclopropylmethyl-3- {2 - [((R) -3-phenylbutyrylamino) methyl] phenyl} pyridine-2-carboxamide

The compound was prepared according to the synthesis method described in WO 0246162.

Example 14:

Benzyl {2- [3- (2,4-difluorobenzylcarbamoyl) pyridin-2-yl] benzyl} carbamate

The compound was prepared according to the synthesis method described in WO 0246162.

Example 15:

Benzyl {4- [3- (3-methylbutylcarbamoyl) phenyl] pyridin-3-yl-methyl} carbamate

The compound was prepared according to the synthesis method described in WO 0246162.

Example 16:

N- (3-Methylbutyl) -2 '- {[3- (4-methoxyphenyl) propionylamino] methyl} -6-methylbiphenyl-3-carboxamide

The compound was prepared according to the synthesis method described in WO 0244137.

Example 17:

N-Indan-1-yl-2-methyl-5- (3-methylbutylsulfamoyl) benzamide

The compound was prepared according to the synthesis method described in WO 00100573.

PHARMACOLOGICAL RESEARCH

A) Determination of activity for the TASK-1 channel on Xenopus oocytes

TASK-1 mouse or human channels were expressed in Xenopus oocytes. For this purpose, the oocytes were first isolated from Xenopus levis and defoliated. Then, the in vitro synthesized TASK-1 protein encoding RNA was injected into these oocytes. After a two-day expression of the TASK-1 protein, TASK-1 currents on oocytes were measured using a 2-microelectrode potential fixation method. Typically, in these measurements, TASK-1 channels were activated using power surges up to 40 mV (mV), lasting 250 ms (mc). The cuvette was washed with a solution of the following composition: NaCl 96 mm, KCl 2 mm, CaCl ₂ 1.8 mm, MgCl ₂ 1 mm, HEPES 5 mm (titrated NaOH to pH 7.4). These experiments were carried out at room temperature. The following hardware was used for data collection and analysis: Geneclamp amplifier (Axon Instruments, Foster City, USA), MacLab D / A converter, and related software (ADInstruments, Castle Hill, Australia). The inventive substances were tested by adding them at various concentrations to the solution in the cuvette. The degree of exposure to substances was calculated as the percentage of inhibition from the current TASK-1 control, which was recorded without adding the substance to the solution. Then the data were adjusted according to the Hill equation to determine for specific substances the concentrations corresponding to 50% of the maximum inhibition (IC ₅₀ values).

In this way, the following IC ₅₀ values were determined for the following compounds:

Compound IC ₅₀ (μmol) TASK 1 (mouse) IC ₅₀ (μmol) TASK 1 (human) Example 1
(R-enantiomer) 0.15 0.10 Example 1
(S-enantiomer) 0.80 Example 2 0.43 0.57 Example 3 0.82 Example 4 0.65 Example 5 2.08 Example 6 1.15 Example 7 1.06 Example 8 0.55 Example 9 2,37 Example 10 1.19 Example 11 0.35 Example 12 3.36 Example 13 3.07 Example 14 2.90 Example 15 1.83 Example 16 2.77

B) Determination of activity of compounds on the TASK-1 channel using FLIPR technology

The inhibition of human TASK-1 current on CHO cells in which the human TASK-1 channel is expressed by the compounds described in the examples at a concentration of 10 μmol / L was measured using the FLIPR test. This gave the following inhibition characteristics:

Compound  Inhibition at 10 μmol / L Example 1
(R-enantiomer) 81% Example 1
(S-enantiomer) 58% Example 2 77% Example 3 82% Example 5 88% Example 6 68% Example 7 57% Example 8 77% Example 9 60% Example 10 61% Example 11 88% Example 12 73% Example 13 65% Example 14 fifty% Example 15 70%

C) Determination of the activity of compounds on the TASK-3 channel using a patch clamp technique

Using the patch clamp technique, the inhibition of human TASK-3 current was measured on CHO cells in which the human TASK-3 channel is expressed by the compounds described in the examples. In the eukaryotic expression vector p658, which contains DHFR (dihydrofolate reductase) resistant gene [reference: Gene 1994 (149), 341-344, 1994], human TASK-3 cDNA (cDNA) was cloned to obtain a TASK-3 cell line (Genbank , Accession Number AF248241). DHFR-free CHO (Chinese Hamster Ovary) cells were transfected with the TASK-3 expression construct using Fugene reagent (Roche Biochemicals) according to the manufacturer's instructions. Recombinant DHFR-positive cells were cultured in MEM (minimal essential medium) supplemented with 10% dialyzed fetal calf serum. Analysis for TASK-3 expression of the obtained cell clones was performed using fluorescence activity testing on a FlexStation instrument (Molecular Devices), with a dye sensitive to membrane response (Molecular Devices FMP Dye Kit). Functional expression of TASK-3 showed an increase in the fluorescent signal after adding 50 mM KCl to the cells, which corresponded to depolarization of the membrane potential. Then, TASK-3-positive cell clones were analyzed using the patch-clamp technique for effective potassium currents. For subsequent studies, the CHO-244-8-1 cell clone was selected as a typical cell clone.

For the study of substances, cells were introduced into a measuring chamber, which is mounted in an inverted microscope. On visual observation, a borosilicate glass micropipette was gently pressed onto the cage. Smooth suction creates a highly stable insulation between the glass pipette and the cage. A sharp suction broke the membrane area and caused the entire cell to leak. By applying voltage surges from -140 mV to +80 mV using an electronic patch clamp amplifier (Axopatch-1D), electric current was recorded under conditions of voltage surges. The action of the substance was recorded by adding it to a cuvette with a solution in increasing concentrations. The concentration corresponding to 50% of the maximum current inhibition (IC ₅₀ value) was determined by adjusting the curve, matching it with Hill's mathematical equation.

The following IC ₅₀ values were determined by this analysis:

Compound IC ₅₀ (μmol / L)
TASK3 (Human) Example 1
(R-enantiomer) 1.0 μM

D) Respiratory effect study of rabbits

Apnea was induced in a rabbit by infusion of narcotic propofol, 10 mg / kg / min. The excipient used for the compound of Example 1 (R-enantiomer) was DMSO / PEG (DMSO / PEG) (0.2 ml / 1.8 ml). The time from the start of propofol infusion until the onset of apnea was recorded. In the control, an apnea attack occurred after approximately 2.92 minutes; after intravenous (i.v.) administration of 10 mg / kg of the compound of Example 1 (R-enantiomer), the onset of apnea slowed down and did not occur until 5.63 minutes passed after the start of propofol infusion (table 1).

TABLE 1
(p <0.001; amount n = 13) Basal Filler Example 1
(R-enantiomer) Average 2.87 min 2.92 min 5.63 min Standard deviation 0.69 min 0.60 min 2.08 min

Studies show the effect of the compound of Example 1 against the onset of attacks of central apnea.

E) Study of the effects on the electromyographic activity of the chin-muscle and minute respiratory rate in rats

The effect of the compound of Example 1 (R-enantiomer) and the compound of Example 2 on the electromyographic activity of the chin-lingual muscle and on respiratory stimulation in a male vagotomized rat weighing 250 to 300 g, anesthetized with urethane-chloralosis was studied. For this purpose, EMG activity of the chin-muscle was measured using EMG electrodes. The respiratory stimulating effect was investigated by measuring the minute volume of respiration using a tracheal cannula. In these studies, 1, 3 mg / kg and 10 mg / kg of the compound of Example 1 (R-enantiomer) and the compound of Example 2, with glycofurol (50%) as an excipient, were intravenously administered to rats sequentially with a 15-minute interval. As a positive control of stimulation of the activity of the chin-muscle and minute respiratory volume, CO _{2 was used} .

TABLE 2
The effect of the compounds of example 1 (R-enantiomer) on EMG activity of the chin muscle
in anesthetized rats (number, n = 8). EMG activity is given in arbitrary units Example 1
(R-enantiomer) EMG activity Basal 5%
CO ₂ Basal Filler Basal 1 mg / kg 3 mg / kg 10 mg / kg Average 3.83 5.13 3.66 3.85 3.52 4.45 5.59 7.18 Standard error 0.48 0.64 0.42 0.46 0.35 0.44 0.57 0.49 Compared to filler 0.0001 0.001 0.0001 0.0001

TABLE 3 The effect of the compound of example 1 (R-enantiomer) on respiration (minute respiration volume in ml / min) of anesthetized rats (amount, n = 8) Example 1
(R-enantiomer) EMG activity Basal 5%
CO ₂ Basal Filler Basal 1 mg / kg 3 mg / kg 10 mg / kg Average 158 237 157 204 168 246 317 375 Standard error 12 22 9 twenty eleven 21 31 25 Compared to filler 0,0257 n.s. 0,0306 <, 0001

TABLE 4 Example 2 Effects of compounds on the EMG activity genioglossal muscles in anesthetized rats (number, n = 11). EMG activity is given in arbitrary units Example 2 EMG activity Basal 5%
CO ₂ Basal Filler Basal 1 mg / kg 3 mg / kg 10 mg / kg Average 2,37 3.15 2,31 2.46 2.17 3.15 3,55 3.82 Standard error 0.39 0.51 0.41 0.42 0.39 0.54 0.59 0.63 Compared to filler 0.001 0.001 0.001 0.001

TABLE 5 Example 2 Effects of compounds on respiration (respiratory minute volume in ml / min) in anesthetized rats (number, n = 11) Example 2 EMG activity Basal 5%
CO ₂ Basal Filler Basal 1 mg / kg 3 mg / kg 10 mg / kg Average 140 209 146 178 151 253 279 291 Standard error 8 13 7 eleven 7 16 twenty 26 Compared to filler - 0.001 0.001 0.001

The compounds of example 1 (R-enantiomer) and example 2 significantly stimulate both the electromyographic activity of the chin-muscle (tables 2 and 4), which increases the muscle tone of the upper respiratory tract and minute respiratory volume (tables 3 and 5). Increased muscle tone and breath-stimulating effects prevent respiratory distress, such as attacks of central or obstructive sleep apnea and snoring.

F) Study of the compatibility of these compounds in rats

With the oral administration of 1000 mg / kg of the compound of Example 1 (R-enantiomer), no side effects were detected.

Claims (6)

1. The use of compounds of formula Ib for the manufacture of a medicament for the treatment or prevention of sleep respiratory disorders, attacks of central and obstructive sleep apnea, upper respiratory tract obstruction syndrome and snoring

in which R (1) is C (O) OR (9), COR (11);
R (9) is C _x H _2x -R (14);
x takes values 0, 1, 2 or 3,
R (14) is cycloalkyl having 5 or 6 carbon atoms, phenyl,
where phenyl is unsubstituted or substituted by 1 or 2 substituents selected from the group consisting of F, Cl, CF ₃ , OCF ₃ , alkyl having 1, 2 or 3 carbon atoms, alkoxy having 1 or 2 carbon atoms;
R (11) is defined similarly to R (9);
R (2) is a hydrogen atom;
R (3) is C _y H _2y —R (16);
y takes values 0, 1, 2 or 3,
where y cannot be 0 when R (16) is OR (17);
R (16) is alkyl having 1, 2 or 3 carbon atoms, cycloalkyl having 5 or 6 carbon atoms, CF ₃ , OR (17), phenyl or pyridyl,
where phenyl or pyridyl are unsubstituted or substituted by 1 or 2 substituents selected from the group consisting of F, Cl, CF ₃ , OCF ₃ , alkyl having 1, 2 or 3 carbon atoms, alkoxy having 1 or 2 carbon atoms;
R (17) is hydrogen;
R (4) is a hydrogen atom or an alkyl having 1 or 2 carbon atoms;
R (5), R (6), R (7) and R (8) each independently, is a hydrogen atom, F, Cl, CF ₃ , alkyl having 1, 2 or 3 carbon atoms;
R (30) and R (31) each is a hydrogen atom;
and / or physiologically compatible salts of the compounds of formulas Ib. 2. The use according to claim 1 for the manufacture of a medicament for the treatment or prevention of sleep apnea attacks. 3. The use according to claim 1, where the compounds are selected from the group consisting of:
N- (2-pyridin-3-yl-ethyl) -2 ′ - {[2- (4-methoxyphenyl) acetylamino] methyl} biphenyl-2-carboxamide,
N- (2- (R) -hydroxypropyl) -2 ′ - (α- (S) -methylbenzyloxycarbonylaminomethyl) biphenyl-2-carboxamide,
N- (2,4-difluorobenzyl) -5-chloro-2 ′ - {[2- (4-methoxyphenyl) acetylamino] methyl} biphenyl-2-carboxamide,
benzyl {2 ′ - [methyl (2-pyridin-2-yl-ethyl) carbamoyl] biphenyl-2-yl-methyl} carbamate,
and / or their physiologically compatible salts. 4. The use of compound 1b according to claim 1 for the preparation of a medicament for intravenous administration. 5. The use of compound 1b according to claim 1 for the preparation of a medicament for oral administration. 6. The use of compound 1b according to claim 1 for the preparation of a medicament for nasal administration.